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Abstract
Drug transport proteins are important determinants of drug absorption, tissue accumulation,
and elimination from the body, and there is growing appreciation for the contribution of
altered drug transporter function to interindividual variability in drug response. The organic
anion-transporting polypeptides (OATPs/SLCO) are uptake transporters with broad substrate
specificity. Notably, the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors, or statins, are commonly prescribed OATP substrates.

The OATP1B subfamily, expressed predominantly in the liver, is of particular importance to
statins, which require hepatic entry to exert their low-density lipoprotein cholesterol lowering
effect. We aimed to identify molecular determinants of substrate specificity in the human
OATP1B subfamily in vitro, and found three regions required for transport of a non-statin
substrate, cholecystokinin-8, thus improving our understanding of OATP1B transport
mechanism. We employed Oatp1b2-/- mice to model reduced OATP1B function in humans,
and observed liver-to-plasma ratios of atorvastatin and rosuvastatin were lower in Oatp1b2-/mice compared with wild-type animals, further emphasizing the importance of this OATP
subfamily to hepatic drug uptake.

One challenge to statin therapy is the risk for muscle toxicity associated with elevated
systemic statin exposure. We assessed intraindividual variability in statin pharmacokinetics
in human subjects, and found a correlation in exposure to atorvastatin and simvastatin, which
are both metabolized by cytochrome P450 3A (CYP3A). In contrast, atorvastatin and
simvastatin exposure were not correlated with rosuvastatin, a statin that is transported but not
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significantly metabolized, thus illustrating the interplay between transport and metabolism
that influences statin pharmacokinetics.

Though numerous clinical trials have investigated statin effectiveness, interindividual
variability in statin pharmacokinetics in a clinical setting is not well understood. We
characterized atorvastatin and rosuvastatin concentration in 299 patients at London Health
Sciences Center, and observed 45-fold variability. Genetic variants in SLCO1B1 and ABCG2
were associated with rosuvastatin concentration. Atorvastatin concentration was associated
with SLCO1B1 variants and with 4β-hydroxycholesterol concentration, a marker of CYP3A
activity. Lathosterol, a marker of HMG-CoA reductase function, was not associated with
statin concentration in our population.

Taken together, these studies further our understanding of OATP function, both in vivo and
in vitro, and the contribution of OATPs to pharmacokinetics and drug response.

Keywords
Organic anion-transporting polypeptides, solute carrier transporters, ATP-binding cassette
transporters, transporter knockout mice, drug transporter polymorphisms, drug transporter
pharmacogenetics, hepatic uptake transport, statins, statin transport, statin pharmacokinetics
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INTRODUCTION TO TRANSPORTER
PHARMACOGENETICS 1

Reproduced from: DeGorter MK and Kim RB. “Introduction to Pharmacogenomics of
Drug Transporters" in Pharmacogenomics of Human Drug Transporters: Clinical
Impacts. Ishikawa T, Kim RB and Konig J, Eds.; John Wiley and Sons Inc: Hoboken,
New Jersey, 2013. This material is reproduced with permission of John Wiley & Sons,
Inc.
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1.1

Introduction

Understanding the molecular mechanisms and clinical relevance of interindividual
variability in drug response remains an important challenge. Pharmacogenomics, the
study of genetic variation in the genes that influence drug effect, can provide insight into
interindividual variability and a more accurate prediction of drug response than may be
obtained by relying solely on a patient’s clinical information. The goal of drug transporter
pharmacogenomics is to understand the impact of genetic variation on the function of
transporters that interact with medications. For many drugs in clinical use, transporters
are important determinants of absorption, tissue accumulation, and elimination from the
body, and thereby transporters significantly influence drug efficacy and toxicity. Adverse
drug reactions can result from toxicity associated with high drug concentrations and lack
of efficacy can result from subtherapeutic drug exposure. By understanding the genetic
basis for drug transporter activity, it will be possible to enhance a predictive approach to
individualization of drug therapy.

The purpose of this chapter is to highlight the advances in transporter pharmacogenomics
that have been made since polymorphisms in drug transporter genes were first described
in the late 1990s (1-3). As we enter the genomic era of medicine, pharmacogenomics will
inform prescribing practices to maximize drug efficacy while minimizing risk for
toxicity. Given the importance of transporters to the absorption, distribution, and
elimination of many drugs, there is no doubt that transporter pharmacogenomics will
make significant contributions to this aim.
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1.2

Overview of drug transporters

Membrane transporters have diverse and important roles in maintaining cellular
homeostasis by the uptake and efflux of endogenous compounds to regulate solute and
fluid balance, facilitate hormone signaling, and extrude potential toxins. Drug transport
proteins are a functional subset of membrane transporters that also interact with drugs
and their metabolites. Compounds that rely on carrier mechanisms tend to be polar and
bulky, and less likely to pass through cell membranes by simple diffusion. Transporter
substrates include numerous drugs, their hydroxylated metabolites and the glutathione,
sulfate or glucuronide-conjugated products of Phase II metabolism. Transporters that are
expressed in the epithelia of intestine, liver, and kidney are of particular importance for
vectorial or directional movement of drugs, resulting in efficient and rapid drug
absorption, distribution, metabolism, and elimination. Moreover, expression of drug
transporters on the basolateral versus apical domain of polarized epithelial cells in organs
such as the intestine and liver may also be critical for a drug to enter the tissue and
interact with its target (4-5).

Membrane transporters are comprised of multiple transmembrane domains (TMDs) that
form a pore in the membrane through which the substrates pass. These domains are
joined by alternating intracellular and extracellular loops which, together with TMDs,
facilitate substrate recognition, binding, and translocation. The functional mechanism and
conformational changes required for transport are not completely understood, and remain
an active area of investigation (6). Of particular interest to transporter pharmacogenomics
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is the ability to predict the functional effect of novel mutations that are discovered in
individual genomes.

Drug transporters belong to two major classes, the solute carrier superfamily (SLC), and
the ATP-binding cassette (ABC) superfamily. In the human genome there are 350
transporters in the SLC superfamily, and 48 ABC transporters; these transporters are
divided into subfamilies based on sequence homology (5). ABC transporters are
distinguished by the presence of an intracellular nucleotide binding domain that catalyzes
the hydrolysis of ATP to generate the energy required to transport substrates against their
concentration gradient (7). In contrast, SLC transporters utilize facilitated diffusion, ion
coupling or ion exchange to translocate their substrates. In some cases, transport relies on
an ion gradient that is actively maintained by ABC transporters (8).

Transporter function may be influenced by multiple factors, and interindividual
variability in transporter function is now recognized as a major source of variability in
drug disposition and response. Drug transporters can be inhibited by numerous
compounds, typically by competition for recognition and binding, resulting in unexpected
pharmacokinetics of substrate drugs, and drug-drug interactions. Genetic variants may
also affect transporter function, and, in recent years, the discovery of genetic variation in
drug transporters has opened up an area of research in transporter pharmacogenomics (5;
9).
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1.3

Overview of pharmacogenomics

The study of inherited differences in drug response dates back to observations of
inherited differences in metabolism by Garrod in 1902 (10), although the field did not
come into its own until the 1950s and 1960s, when Kalow first used the term
pharmacogenetics to describe the emerging discipline (11). In the late 1980s, molecular
advances provided a mechanistic explanation for these findings (12-13). Many early
achievements in pharmacogenetics described the effect of genetic variation in
cytochrome P450 (CYP) drug metabolizing enzyme genes on metabolite concentrations.
Pharmacogenomics studies have benefited from having well defined phenotypes: a
pharmacokinetic measure such as the plasma or urine concentration of a drug or its
metabolite, or a measure of drug response, such as a change in blood pressure or heart
rate. For monogenic traits, this approach has led to new insights in our understanding of
the factors underlying drug disposition and response, and provided a solid foundation to
study traits that are influenced by multiple genes and other clinical factors. Today,
pharmacogenomics encompasses a broad spectrum of genes involved in metabolism as
well as transport, and in drug targets and related pathways (14).

Genetic variants include single nucleotide polymorphisms (SNPs), which are typically
present in >1% of the population, while more rare variants are considered to be genetic
mutations. SNPs in the coding regions of proteins may be classified as synonymous or
non-synonymous, depending on whether the amino acid sequence is altered in the variant
allele. Single nucleotide polymorphisms may also come in the form of small insertions or
deletions, which result in frameshift of amino acid sequence or premature truncation of
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the protein, and likely a non-functional product (15). Duplication or deletion of larger
regions of genomic sequence (>50bp) are classified as copy number or structural variants
(16). A classic example of copy number variation comes from the field of
pharmacogenomics: CYP2D6 is commonly duplicated or deleted, resulting in profound
differences in the rate of metabolism of its substrate drugs in individuals with these
changes (17). There is a growing appreciation for the importance of structural differences
as a source of variation in the human genome, and further study of this variation as it
relates to transporter genes is expected (16).

Pharmacogenomic information may be used to predict treatment outcomes and choose
the best drug and its optimal dose. Pharmacogenomics may also be used to predict a
patient’s risk for an adverse drug reaction, including drug-drug interactions that may be
more severe depending on genetic changes. At the time of writing, the United States Food
and Drug Administration (FDA) listed nearly 80 drugs for which pharmacogenomic
biomarkers in over 30 genes were included in some part of the label recommendations.
To date, the FDA has focused on drug metabolizing enzymes and target proteins;
however, transporter genes are expected to be added in the future, following the work of
the International Transporter Consortium, sponsored by the FDA’s Critical Path Initiative
(5).
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1.4

Pharmacogenomics of drug transporters

Transporter polymorphisms may increase or reduce an individual’s overall exposure to a
substrate, depending on the tissue expression and localization of the transporter. For
example, reduced function uptake transporters on the luminal membrane of the intestine
would result in reduced systemic exposure of its substrate, whereas reduced function
uptake transporters on the basolateral membrane of the liver or kidney may result in
increased systemic exposure if the drug in question relies on these organs for its
elimination. On the other hand, reduced function of ABC efflux transporters present on
the luminal membrane of the intestine will result in increased plasma concentration of the
substrate drug, as less drug is returned to the intestinal lumen by the transporter. In some
cases, the precise in vivo contribution of a transporter may be difficult to define,
particularly if the transporter is present in multiple tissues, or has overlapping function
with transporters of similar expression patterns. The extent of phenotypic variation
observed will depend on how much the substrate relies on the single transporter in
question, and the extent of genetic variation present in the other transporters,
metabolizing enzymes, and targets that interact with the drug.

To date, the best studied transporter polymorphisms have been those in the coding
regions of transporter genes. Some variants cause reduced trafficking of the transporter to
the cell membrane, resulting from incorrect folding or an inability to interact with
molecular chaperones, and other variants may affect substrate recognition or binding.
Certain amino acid changes, particularly in substrate binding regions, have been shown to
alter transport in a substrate-specific fashion, making it difficult to fully predict the effect

8

of a polymorphism on transport of a particular compound without testing that compound
directly. Although numerous polymorphisms in transporter genes have been identified,
not all polymorphisms appear to affect transporter function. One method to test the
function of a SNP is to express its protein product and measure its transport function in
vitro. Of 88 protein-altering variants studied in 11 SLC transporters, 14% had decreased
or total loss of functional activity in in vitro assays (15). This is likely an
underestimation, due to the possibility of substrate-specific differences in effect.

Analysis of large numbers of SNPs in the coding regions of transporters demonstrated
that genetic diversity is significantly higher in loop domains compared with TMDs,
suggesting there is selective pressure against amino acid changes in these regions (18).
Polymorphisms may also occur in intronic regions, affecting splicing, or in promoter and
enhancer regions, affecting RNA expression. Analysis of proximal promoter region
variation showed that SLC transporter promoters are more likely to contain variants than
ABC transporter promoters, and highly active promoters are more likely to contain
variants than less active ones (19). Genetic diversity in transporter genes also appears to
be related to ethnicity. In a study of 680 SNPs identified from samples representing five
ethnic populations, only 83 SNPs were present in all five populations (18). Thus
differences in transporter polymorphism frequency may account for some variability in
drug response observed across ethnicities.
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1.5

Techniques to study drug transporter function

The application of advances in molecular biology techniques to the study of transporters
over the last twenty years has made significant contribution to our understanding of
transporter biology. In vitro, transporter activity is often characterized in primary cells
and in expression systems, including transiently and stably transfected cultured human
cell lines, inside-out membrane vesicles, and insect cells. One challenge to studying
transporters in vivo is the overlapping substrate specificity and tissue distribution of
many transporters, which can lead to difficulties in the precise identification of the
transporter(s) responsible for a particular effect. Knockout mouse models of transporters
have proven to be useful to delineate the contribution of certain transporters to drug
disposition (20). Knockout mice exist for many of the SLC and ABC transporters, and
double and triple ABC transporter knockout models have been used to characterize the
contribution of multiple transporters with overlapping substrate specificities (21). It is
important to bear in mind that there are species-related differences in transporter
expression and substrate specificity that may make it difficult to interpret and extrapolate
the results obtained in mice to the human situation. The relative contribution of a given
transporter in vivo has also been examined by drug-specific pharmacokinetic and
pharmacodynamic studies in individuals with and without polymorphisms in the
transporter gene of interest.

In the last decade, the field of genomics has developed rapidly, with the sequencing of
the human genome (22-23) and subsequent efforts to determine haplotype structure by
the HapMap project (24), and sequence variation by the 1000 Genomes Project (25).

10

Genome-wide association studies (GWAS) incorporating clinical and genetic data have
been widely used to identify genetic variants that predict risk for disease and also to
assess drug response or toxicity. For pharmacogenomics studies, GWAS offer to identify
candidate genes unrelated to our current knowledge of drug mechanism (26).

Methods for detecting transporter polymorphisms and predicting the functional
consequences of unique polymorphisms in real time will be required to use
pharmacogenomics in the clinical setting. To address this need, genotyping platforms for
a focused set of important pharmacogenetic genes are being developed for clinical use
(27). QSAR and molecular dynamics simulations are in silico approaches that are active
areas of research aimed at addressing this challenge of SNP prediction (28).

1.6

Transporter pharmacogenomics in drug discovery

and development
An understanding of transporter pharmacogenomics is important for the design and
development of new drugs that are safe and effective. Transporters interacting with drug
candidates may be identified during the preclinical stage of drug development, taking into
consideration the limitations inherent to extrapolating in vitro and animal data to predict
human response. For this reason, pharmacogenomic studies in later phases of drug
development and post marketing surveillance are crucial to identify potential transportermediated drug interactions, and individuals with transporter polymorphisms who may
require dose adjustment or an alternative compound (29). The International Transporters
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Consortium is a group of academic, industry, and regulatory leaders formed to create
guidelines for the systematic inclusion of transporter studies in the drug development and
approval process (5).

1.7

Clinical implications of transporter

pharmacogenomics
As our understanding of transporter pharmacogenomics matures, and pharmacogenomics
technologies are more widely adopted in the clinic, transporter genomics could be used to
select an appropriate dose, or the best medication from a particular class of compounds,
and identify those individuals who may be at increased risk for an adverse drug reaction.
Transporters that affect drug response are numerous and diverse in their effect; key
examples from the SLC and ABC superfamilies are summarized in Tables 1.1 and 1.2,
respectively.

P-glycoprotein is an example of an efflux transporter that can significantly limit the
accumulation of its substrates in certain tissues. The expression of P-glycoprotein at the
blood brain barrier prevents the central nervous system accumulation of drugs such as
protease inhibitors, and its overexpression in cancer cells is associated with a multidrug
resistant phenotype (30). Genetic variants in the cation transporter OCT1 (SLC22A1)
have been associated with reduced efficacy of metformin, an antidiabetic drug that targets
the liver as its site of action (31). The organic anion-transporting polypeptide 1B1
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Table 1.1 Drug transporters of the solute carrier superfamily

Transporter
(Gene)

Tissue(s) of
predominant
expression
in humans

Key drug
substrates

Key
inhibitors

SNPs
associated
with drug
response

Ref

OCT1
(SLC22A1)

hepatocyte
(basolateral)

metformin,
oxaliplatin

quinine

multiple
associated
with
metformin
response

(32)

OCT2
(SLC22A2)

renal
proximal
tubule
(basolateral)

metformin,
oxaliplatin

cimetidine

none to date

(32)

MATE1
(SLC47A1)

hepatocyte
(canalicular
membrane);
renal
proximal
tubule
(luminal)

cimetidine,
metformin,
procainamide

cimetidine,
pyrimethamine

possibly
rs2289669

(32)

OAT1
(SLC22A6)

renal
proximal
tubule
(basolateral)

acyclovir

probenecid,
NSAIDs

none to date

(33)

OAT3
(SLC22A8)

renal
proximal
tubule
(basolateral)

NSAIDs,
furosemide

probenecid,
NSAIDs

none to date

(33)

OATP1B1
(SLCO1B1)

hepatocyte
(basolateral)

statins,
repaglinide

rifampicin,
gemfibrozil
cyclosporine

c.521T>C
(rs4149056)

(34)

OATP1B3
(SLCO1B3)

hepatocyte
(basolateral)

statins,
taxanes

rifampicin,
cyclosporine

possibly
c.334T>G
(rs4149117)

(35)

OATP2B1
(SLCO2B1)

hepatocyte
(basolateral);
enterocyte
(luminal)

statins,
fexofenadine

cyclosporine

possibly
c.935G>A
(rs12422149)

(35)
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Table 1.2 Drug transporters of the ATP-binding cassette superfamily

Transporter
(Gene)

Tissue(s) of
predominant
expression
in humans

Key drug
substrates

Key
inhibitors

SNPs
associated
with drug
response

Ref

P-gp
(ABCB1)

hepatocyte
(canalicular);
enterocyte
(luminal);
blood-brain
barrier

HIV protease
inhibitors,
antineoplastics

cyclosporine,
verapamil

possibly
c.3435T>C
(rs1045642)

(30)

BSEP
(ABCB11)

hepatocyte
(canalicular)

pravastatin

cyclosporine,
glibenclamide

possibly
p.V444A
(rs2287622)

(3637)

MRP2
(ABCC2)

hepatocyte
(canalicular)

β-lactam
antibiotics,
methotrexate,
multiple
Phase-II
conjugates

cyclosporine

none to date

(36)

MRP4
(ABCC4)

hepatocyte
(basolateral);
renal
proximal
tubule
(luminal)

nucleosidebased
antivirals,
methotrexate,
topotecan

dipyridamole,
losartan

possibly
p.E757K
(rs3765534)

(38)

BCRP
(ABCG2)

hepatocyte
(canalicular);
enterocyte
(luminal);
blood-brain
barrier

statins,
antineoplastics

dipyridamole,
cyclosporine

c.421C>A
(rs2231142)

(39)
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(OATP1B1/SLCO1B1) polymorphism c.521T>C has been associated with increased risk
for statin-induced muscle toxicity (40) and genotyping patients for this variant has been
proposed to identify those at greater risk for side effects (41).

Transporter pharmacogenomics have not yet been widely used in a clinical setting.
Moving forward, studies are needed to show the risk-benefit ratio of a drug is improved
by pharmacogenomic testing, and some efforts are being made to determine the key
components to be included in pharmacoeconomic evaluations of pharmacogenomic tests
(42). As sequencing becomes more cost-efficient, the possibility of sequencing relevant
genes or even genomes in a clinical setting poses a new challenge of interpreting
pharmacogenomic information on an individual level (43).

Finally, it is important to bear in mind that many factors contribute to variability in drug
responsiveness, including renal and hepatic function, underlying disease processes, and
drug interactions. At the end of the day, a patient’s actual drug response phenotype, in
terms of efficacy and toxicity, is the key clinically relevant endpoint, and
pharmacogenomics should be integrated with other parameters such as drug levels,
biomarkers, and measures of drug response in order to provide truly personalized
medicine.
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1.8

Conclusion

Genetic variation in transporters contributes significantly to observed interindividual
variability in drug response. In the future, systematic inclusion of drug transporter studies
that assess genetic variation, whether affecting transporter function or expression, will be
essential to the development of drugs that are safe and effective. There is little doubt drug
transporter pharmacogenomics is expanding rapidly and new insights will continue to
inform improved drug prescribing and thereby enhance the delivery of optimal medical
care.
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2.1

Introduction

Optimizing drug efficacy and minimizing drug toxicity requires that the drug reach its
target at adequate concentration, without excessive accumulation in other tissues. For
many drugs in clinical use today, intracellular concentration is determined by the balance
in activity of multiple uptake and efflux transporters that facilitate the drugs’ movement
across biological membranes. Transporters are large, membrane-bound proteins
expressed in tissues throughout the body; those found in the epithelia of major organs of
absorption and secretion such as liver, intestine, and kidney and in sanctuary sites such as
the brain, testes, and placenta are of particular importance in drug disposition (Figure
2.1). Interindividual variation in transporter activity can arise from numerous factors,
including genetic heterogeneity, certain disease processes, concomitant medications, and
herbals and dietary constituents that may inhibit or induce transporter expression or
activity (1-3).

Transporter function has been studied extensively in vitro through the use of cRNAinjected Xenopus laevis oocytes and transfected mammalian cell lines. Knockout mice
and other animal models have provided significant insights into the role of transporters in
vivo, particularly when multiple transporters with overlapping substrate specificities are
expressed in the same tissue. However, species-related differences in transporter
expression and substrate specificity are relatively common and need to be considered
when the results of experiments in rodent models are being interpreted. In humans, the
role of transporters in drug efficacy and toxicity has been indirectly shown by inhibition
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Figure 2.1 Expression of transporters with major roles in drug efficacy or toxicity.
Tissues shown are (a) human intestinal epithelia, (b) kidney proximal tubule epithelia, (c)
hepatocytes and (d) brain capillary endothelial cells. Transporters discussed in the text
are coloured red. NTCP, ASBT, and BSEP are bile acid transporters. PEPT1 and PEPT2
transport small peptide fragments. OCTN1 and OCTN2 transport organic cation and
carnitine. Abbreviations: ASBT, apical sodium-dependent bile acid cotransporter; BCRP,
breast cancer resistance protein; BSEP, bile-salt export pump; MATE, multidrug and
toxin extrusion; MRP, multidrug resistance-associated protein; NTCP, sodium-dependent
taurocholate cotransporting polypeptide; OAT, organic anion transporter; OATP, organic
anion-transporting polypeptide; OCT, organic cation transporter; OCTN, organic
cation/carnitine transporter; PEPT, peptide transporter; P-gp, P-glycoprotein
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Figure 2.1 Expression of transporters with major roles in drug efficacy or toxicity
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or induction studies both in healthy volunteers and in patients. Naturally occurring
genetic polymorphisms cause reduced expression or function of specific transporters, an
effect that is not readily achieved by pharmacological inhibitors in most cases. For this
reason, studies in human subjects with genetic polymorphisms have been instrumental in
defining the clinical relevance of certain transporters to drug disposition and response.

Given the critical role of transporters in mediating the pharmacokinetics of many drugs,
transporter studies are an important part of the drug discovery and development process.
A recent report from the International Transporter Consortium provides some guidance
for the circumstances under which transporter studies may be indicated for a new
molecular entity during the drug development process, with the caveat that the proposed
decision structures will continue to evolve as the drug transporter field matures (1).

In this review, we focus on transporters with well-defined roles in drug efficacy and
toxicity. From the solute carrier (SLC) superfamily, these include the organic cation
transporters (OCTs/SLC22A), the multidrug and toxin extrusion transporters (MATE
transporters/SLC47A), the organic anion transporters (OATs/SLC22A), and the organic
anion-transporting polypeptides (OATPs/SLCO). Members of the ATP-binding cassette
(ABC) superfamily important in drug efficacy and toxicity include P-glycoprotein
(MDR1/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and transporters of
the multidrug resistance-associated protein (MRP/ABCC) family.
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2.2

Uptake transporters of the solute carrier

superfamily
The SLC superfamily is a large family of membrane-bound transporters that share 2025% sequence homology. SLC transporters translocate their substrates across biological
membranes through numerous mechanisms, including facilitated diffusion, ion coupling,
and ion exchange, which, in some cases, is driven by an ion gradient that is maintained
by active transporters of the ABC superfamily (4).

2.2.1

Organic cation transporters

Organic cation transporters (OCTs/SLC22A) identified in humans include OCT1
(SLC22A1) and OCT2 (SLC22A2), which are predominantly expressed on the basolateral
membranes of hepatocytes and kidney proximal tubules, respectively, and OCT3
(SLC22A3), which is more widely expressed in tissues throughout the body. OCTs are
uptake transporters that control cellular entry of small, positively charged compounds,
including endogenous substrates, such as monoamine neurotransmitters and creatinine,
and numerous drug substrates, including the platinum-containing antineoplastics, the
antidiabetic metformin, and the histamine H2 receptor antagonist cimetidine (5-7). OCT
expression is highly variable among individuals, which may be a result of genetic
variants or disease processes: A study of OCT1 and OCT3 expression in 150 livers from
Caucasian subjects revealed significant variation that was associated with genetic
polymorphisms and cholestasis (8).
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2.2.2

Multidrug and toxin extrusion transporters

The multidrug and toxin extrusion transporters (MATE transporters/SLC47A) are among
the most recently identified transporters of functional importance to cation transport,
although the existence of a renal efflux transport system had been known for some time
(9). MATE1 (SLC47A1) is expressed throughout the body, but predominantly in the liver
and kidneys, where it is localized to the canalicular membrane of hepatocytes and the
luminal membrane of proximal tubule cells, respectively (10-11). In contrast, MATE2-K,
the protein form of MATE2 (SLC47A2) that has been functionally characterized, is
expressed specifically in the kidney proximal tubule and is localized to the luminal
membranes. Many of the substrates and inhibitors of MATE transporters overlap with
those of OCTs; therefore, the role of MATE transporters in mediating cation transport
and drug-drug interactions in the kidney may have been underestimated in the past (5; 7).

2.2.3

Organic anion transporters

The organic anion transporters (OATs/SLC22A) move small organic anions against their
concentration gradient using a Na+ gradient maintained by Na+/K+-ATPase. Of
particular importance in drug disposition are OAT1 (SLC22A6), which is predominantly
expressed on the basolateral membrane of proximal renal tubules, and OAT3 (SLC22A8),
which is predominantly expressed throughout the kidney and in the choroid plexus,
although both OAT1 and OAT3 are expressed in other tissues in the body. In the kidney,
OAT1 and OAT3 facilitate the uptake of compounds from the blood and share a broad
and partially overlapping substrate specificity. OAT substrates include steroid hormones,
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biogenic amines, and drugs such as the angiotensin converting enzyme inhibitors
captopril and quinaprilat, the angiotensin II receptor blocker olmesartan, and numerous
antibiotics and antivirals. Many drugs in clinical use are inhibitors of OAT transport in
vitro, including antibiotics, antivirals, and nonsteroidal anti-inflammatory drugs
(NSAIDs) (12-13).

2.2.4

Organic anion-transporting polypeptides

The organic anion-transporting polypeptides (OATPs/SLCO) have a wide substrate
specificity for amphipathic molecules, including endogenous compounds such as bile
acids, thyroid hormones, sulfated and glucuronidated hormones, and drug substrates
including rifampicin, methotrexate, antidiabetics, and statins (14-16).

2.2.4.1

Organic anion-transporting polypeptides in efficacy

Of the human OATPs, OATP1B1 (SLCO1B1; previously known as OATP-C, OATP2,
and LST-1) has been studied most extensively, owing to the prevalence of clinically
relevant polymorphisms (17). OATP1B1 is expressed exclusively on the basolateral
membrane of the liver and is thought to be the driving force for hepatic uptake of statins
and certain antidiabetic drugs that target the liver as their site of action. SLCO1B1 is
highly polymorphic (17-18); the most extensively characterized variant is the loss-offunction polymorphism c.521T>C (rs4149056), which has a frequency of approximately
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15% in Asian and Caucasian populations. Aberrant cell surface trafficking of this allele
may result in reduced hepatic uptake of OATP1B1 substrates in affected individuals.

Given that statins target the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase enzyme in the liver, it might be expected that reduced hepatic uptake by
OATP1B1 would be accompanied by reduced efficacy, as the statin does not reach
sufficient concentration in the liver to inhibit the enzyme effectively. This was
demonstrated in studies that showed the SLCO1B1 c.521T>C polymorphism was
associated with the lipid-lowering effect of statins in healthy volunteers (19-21), and in a
small group of patients (22) but the association of SLCO1B1 c.521C>T with reduced
statin efficacy has not yet been convincingly demonstrated in large patient cohorts.

In total, the influence of SLCO1B1 polymorphisms on the pharmacokinetics of over 20
clinically used drugs has been studied (17); these drugs include fexofenadine (23),
irinotecan (24-25), lopinavir (26-27), methotrexate (28), repaglinide (29-31). In addition,
SLCO1B1 c.521T>C has been associated with toxic side effects caused by the anticancer
drugs irinotecan (32-33) and methotrexate (34). Not all in vitro substrates of OATP1B1
appear to be affected by OATP1B1 polymorphisms in vivo, suggesting that for certain
substrates, additional transporters may compensate for loss of OATP1B1 function. For
example, bosentan was described as a substrate of OATP1B1 and OATP1B3 (35);
however, it does not appear that polymorphisms in either of these transporters
significantly influence bosentan pharmacokinetics in vivo (36).
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OATP1B3 (SLCO1B3; previously known as OATP8 and LST-2) is also expressed on the
basolateral membrane of human hepatocytes. In addition to transporting many of the
same compounds transported by OATP1B1, OATP1B3 transports taxanes and numerous
small peptides. Polymorphisms in SLCO1B3 have been identified and assessed for
transport activity (37-38), although evidence for the clinical importance of these
polymorphisms is less clear than for SLCO1B1. Genetic variants in SLCO1B3 were not
associated with paclitaxel or docetaxel pharmacokinetics in Caucasian cancer patients,
despite evidence for OATP1B3-mediated transport of these drugs in vitro (39-41).
SLCO1B3 variants were, however, associated with docetaxel-induced leukopenia in
Japanese cancer patients (42), and Slco1a/1b-/- knockout mice had a twofold increased
exposure to paclitaxel compared with wild-type animals (43). Thus, the role of OATP1B3
in taxane transport is not fully understood, although it is interesting that OATP1B3 is
overexpressed in colorectal and breast cancers, and that its transport activity may be
important in drug entry to tumor cells (44).

The other OATP expressed on the basolateral membrane of human hepatocytes,
OATP2B1 (SLCO2B1; previously known as OATP-B), is also expressed on the apical
membrane of enterocytes, where it may be involved in the intestinal uptake of its
substrates. Reduced plasma levels of the leukotriene receptor antagonist montelukast
were associated with the nonsynonymous SLCO2B1 polymorphism c.935G>A
(rs12422149); individuals with this polymorphism also experienced less improvement in
their symptoms compared with wild-type individuals (45). Reduced exposure to the
OATP2B1 substrate aliskiren following ingestion of apple, orange or grapefruit juice is
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postulated to result from inhibition of intestinal OATP2B1-mediated transport (46-47).
For montelukast, orange juice consumption had an effect on plasma exposure for wildtype carriers but not for SLCO2B1 c.935G>A carriers; the latter had reduced montelukast
exposure regardless of treatment (48).

Oatp1b2 was the first murine Oatp transporter to be studied in a knockout mouse model
and is the closest ortholog of the human OATPs expressed in the liver, OATP1B1 and
OATP1B3. Slco1b2-/- mice had lower liver-to-plasma ratios of the prototypical OATP1B
substrates pravastatin, lovastatin, and rifampicin compared with wild-type controls (4950), indicating the importance of Oatp1b2 in mediating the hepatic uptake of these
compounds. Reduced hepatic uptake of the toxins phalloidin and microcystin-LR in
Slco1b2-/- mice resulted in protection against hepatotoxicity induced by these compounds
(51). There are additional Oatps of the Oatp1a family that are expressed in mouse but not
human liver, and compensation by these transporters in Slco1b2-/- mice may not fully
reflect the effect of OATP1B loss in humans. Slco1a/1b-/- mice with deletion of Oatp1b2,
Oatp1a1, Oatp1a4, Oatp1a5, and Oatp1a6 expression demonstrate significantly reduced
hepatic concentrations and elevated plasma levels of methotrexate and fexofenadine (52),
and provide a model to further elucidate the combined role of the Oatp1a and Oatp1b
families in drug disposition.
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2.2.4.2

Organic anion-transporting polypeptides in toxicity

Numerous studies of statin pharmacokinetics in healthy individuals have demonstrated
that reduced-function SLCO1B1 polymorphisms, particularly c.521T>C, increase the area
under the curve of plasma exposure to nearly all the statins, including atorvastatin (5354), pravastatin (55-61), pitavastatin (62-64), rosuvastatin (53; 65-66), and simvastatin
acid (67) (Table 2.1). Increased systemic statin exposure is thought to be one component
of risk for muscle toxicity, a side effect associated with statin use that can range from
mild to life-threatening in its severity. In 2008, a genome-wide association study
identified a variant in complete linkage disequilibrium with SLCO1B1 c.521T>C to be
the single best predictor of myopathy risk in individuals on high doses of simvastatin
(68). Subsequently, the SLCO1B1 c.521T>C variant was found to be a modest risk
predictor for cerivastatin-induced rhabdomyolysis in a candidate gene study of 185 cases
matched to controls (69). In another study, SLCO1B1 c.521T>C was associated with
severe myopathy induced by simvastatin, but not atorvastatin (70). Analysis of 509
subjects who were randomized to receive low-dose atorvastatin, simvastatin or
pravastatin followed by higher doses of the same drug demonstrated an association
between the same polymorphism and adverse events such as discontinuation, myalgia, or
creatine kinase elevation following the dose escalation (71). Most recently, the incidence
of less severe forms of statin intolerance, as manifested by adjusting the dose or
switching to another statin, was associated with the SLCO1B1 c.521T>C polymorphism
in a study of more than 4,000 diabetic patients (72). Finally, OATP2B1 was identified as
a statin transporter present in muscle tissue, indicating a potential role for statin entry into
muscle tissue as part of the mechanism of statin-associated muscle toxicity (73).
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Table 2.1 Transporter polymorphisms involved in statin pharmacokinetics and response
Statin
atorvastatin

Transporter

Population

Experimental

Effect of

polymorphism

studied

approach

polymorphism

SLCO1B1

Healthy subjects

Candidate gene;

Increased AUC and

(53-

full PK profile

Cmax

54)

Patients

Candidate gene;

Increased incidence

(71)

(n=509)

dose escalation

of muscle toxicity

Patients

Candidate gene;

No association with

(25 cases, 84

case-control

muscle toxicity

controls)

study

ABCG2

Healthy subjects

Candidate gene;

c.421C>A

(n=32)

full PK profile

Healthy subjects

c.521T>C

Ref

(rs4149056)

(70)

Increased AUC

(74)

Candidate gene;

Increased AUC and

(53;

full PK profile

Cmax

65-

(rs2231142)
rosuvastatin

SLCO1B1
c.521T>C

66)
ABCG2

Healthy subjects

Candidate gene;

Increased AUC and

c.421C>A

(n=32)

full PK profile

Cmax

Patients

Candidate gene

Enhanced LDL-C-

(n=386)

(61 genes)

lowering response

Hypercholesterole

Candidate gene

Enhanced LDL-C-

mic patients

(74)

(75)

(76)

lowering response

(n=305)
Myocardial

Candidate gene

Enhanced LDL-C

infarction patients

(6 genes);

lowering response

(n=601)

substudy of RCT

(77)
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Table 2.1 Transporter polymorphisms involved in statin pharmacokinetics and response,
continued
Transporter

Population

Experimental

Effect of

Statin

polymorphism

studied

approach

polymorphism

Ref

simvastatin

SLCO1B1

Healthy subjects

Candidate gene;

Increased AUC and

(67)

c.521T>C

(n=32)

full PK profile

Cmax

Patients

Genome-wide

Increased incidence

(85 cases, 90

association study; of muscle toxicity

controls)

substudy of RCT

Patients

Candidate gene;

Increased incidence

(25 cases, 84

case-control

of muscle toxicity

controls)

study

Patients

Candidate gene;

Increased incidence

(n=509)

dose escalation

of muscle toxicity

Diabetic patients

Candidate gene;

Increased incidence

(n=4196)

Population cohort of statin intolerance
study

(68)

(70)

(71)

(72)
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2.3

Efflux transporters of the ATP-binding cassette

superfamily
ATP-binding cassette (ABC) transporters use energy from the hydrolysis of ATP to move
their substrates across biological membranes and against their concentration gradients,
thereby limiting cellular accumulation of their substrates. Members of this large family
are identified by the presence of a highly conserved ATP-binding motif (3).

2.3.1

P-glycoprotein

P-glycoprotein (MDR1/ABCB1) is an ABC transporter with an important role in
protecting tissues from xenobiotics. The protein was originally identified in cells selected
for multidrug resistance (78) and has subsequently been studied extensively in the context
of normal physiology and tumor biology (79). Of particular importance in drug
disposition is the expression of P-glycoprotein in the apical membrane of enterocytes,
hepatocytes, and kidney proximal tubules, and in the endothelial cells of the blood brain
barrier (79).

As it became apparent that P-glycoprotein was not the only molecule capable of
conferring a multidrug resistant phenotype, two other ABC transporters involved in
multidrug

resistance

were

cloned:

multidrug

resistance-associated

protein

1

(MRP1/ABCC1) (80) and breast cancer resistance protein (BCRP/ABCG2) (81-83).
Expression of these transporters, along with their functional genetic polymorphisms, has
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been implicated in drug response and prognosis for numerous tumor types and
chemotherapeutic agents. Many detailed reviews of ABC transporters and anticancer
therapy have been published (84-85).

P-glycoprotein has broad substrate specificity for structurally divergent compounds; in
general, its substrates are hydrophobic and may be cationic. Substrates of P-glycoprotein
include HIV protease inhibitors, calcium channel blockers, and anticancer drugs of the
vinca alkaloid, anthracycline, and taxane classes. P-glycoprotein is inhibited by numerous
compounds including verapamil, ritonavir, and cyclosporine (79). A great deal of effort
has been expended to identify potent and selective P-glycoprotein inhibitors that may be
used to overcome multidrug resistance, but these efforts have not been as successful as
hoped (86). Mouse P-glycoprotein was recently the first mammalian ABC transporter to
be crystallized and characterized at a high resolution (87). The identification of substrate
and inhibitor binding sites will contribute to an understanding of the mechanism of ABC
transporters in general and assist the effort to design molecules that inhibit P-glycoprotein
in order to overcome multidrug resistance.

The role of P-glycoprotein in reducing the absorption of xenobiotics can be directly
examined by comparing oral drug exposure in Mdr1a/1b-/- mice with wild-type controls.
This model proved to be particularly helpful in outlining the likely in vivo impact of this
transporter on the observed oral bioavailability of substrate drugs such as HIV protease
inhibitors, topotecan, etoposide, tacrolimus, ivermectin, and loperamide (88).
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In addition to limiting oral bioavailability, the expression and function of this efflux
transporter in the endothelial cells that constitute the blood brain barrier appear to be
critical to limiting the central nervous system (CNS) entry of many substrate drugs,
including those predicted to have brain accumulation on the basis of physicochemical
properties such as lipophilicity (89). Endoxifen, the active metabolite of the estrogen
receptor antagonist tamoxifen, is a newly identified P-glycoprotein substrate, with
significantly higher endoxifen concentrations observed in the brains of Mdr1a/1b-/- mice
(90-91). Expression of P-glycoprotein at the blood-brain barrier has also been implicated
in anticonvulsant therapy failure, although its clinical relevance remains controversial
(92). Conversely, limited CNS entry by third generation antihistamines that are Pglycoprotein substrates, such as fexofenadine, has proven to be a desirable property as it
reduces the side effect of sedation (93).

For some drugs that are substrates of BCRP, P-glycoprotein alone does not fully limit
CNS drug entry, and only when both transporters are absent is the magnitude of CNS
drug accumulation significantly enhanced. This has been shown through the use of the
Mdr1a/1b/Bcrp-/- mice for tyrosine kinase inhibitors such as lapatinib, imatinib, sunitinib,
and tandutinib, which are substrates of P-glycoprotein and BCRP (94-97). Species
differences in the brain uptake of radiolabeled P-glycoprotein substrates have been
observed by positron emission tomography, and although the mechanisms for these
differences are not well understood, they may be a consideration for animal studies
conducted in preclinical drug development (98).
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ABCB1 is highly polymorphic, however, the in vivo role of these polymorphisms has not
been consistently demonstrated. To date, hundreds of studies in genotype-defined
subjects have been conducted with numerous P-glycoprotein substrates, and the results
have been mixed (79; 99). The ABCB1 c.3435T>C (rs1045642) variant in particular has
received a great deal of attention but the data are conflicting. These inconsistent findings
may result from different experimental conditions, inadequate sample sizes, or
heterogeneity of the sample population studied. Many substrates that are used as probes
for transporter function are also substrates for drug metabolizing enzymes or other
transporters. For example, transport studies with cyclosporine and tacrolimus may be
complicated by the involvement of CYP3A metabolism, and, in addition to being
transported by P-glycoprotein, fexofenadine is also a substrate of OATPs (100). Thus,
metabolism and transport by proteins other than P-glycoprotein may contribute
significantly to the observed variability in drug disposition. Future studies from current
resequencing efforts with larger sample sizes and more detailed genetic information may
help clarify the influence of genetic polymorphisms in ABCB1.

2.3.2

Breast cancer resistance protein

Breast cancer resistance protein (BCRP/ABCG2) is expressed on the luminal membrane
of enterocytes, with greatest expression observed in the duodenum; it is important for
limiting the oral bioavailability of its substrates (101). BCRP is also expressed on the
canalicular membrane of hepatocytes, where it is involved in facilitating biliary
excretion, and found in sanctuary sites such as the blood-brain barrier, placenta, and
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testes. BCRP substrates include numerous anticancer agents, such as the topoisomerase II
inhibitor etoposide, the camptothecin derivatives topotecan and irinotecan, and the
tyrosine kinase inhibitors imatinib and gefitinib. Other substrates of BCRP include
statins, antibiotics, numerous environmental toxins, and endogenous substrates such as
conjugated steroid hormones, folates, and uric acid (102-104).

Bcrp1-/- mice have been useful in elucidating the relative contribution of Bcrp1 to drug
absorption, distribution, and excretion in tissues where other ABC transporters with
overlapping function may be present. The first in vivo evidence for another transporter
active along with P-glycoprotein was the observation that the oral bioavailability of
topotecan, a shared P-glycoprotein and Bcrp1 substrate, was significantly increased when
the Bcrp1 and P-glycoprotein inhibitor GF120916 was coadministered with topotecan to
Mdr1a/1b-/- mice (105). Since these early results, many studies in Bcrp1-/- mice have been
conducted in order to better elucidate the role of BCRP in drug penetration of the CNS
and in oral bioavailability (106).

Comparison of single ABC transporter gene knockout mice with multiple ABC
transporter gene knockout mice may be useful in understanding the overlapping functions
of BCRP and P-glycoprotein with members of the MRPs, as demonstrated by studies of
methotrexate pharmacokinetics in double and triple knockout animals. For example,
plasma concentration of the toxic metabolite 7-hydroxymethotrexate was not
significantly different in Bcrp1-/- mice, but 6.2-fold increased in Mrp2-/- mice, and 12.4fold increased in Mrp2;Bcrp1-/- mice compared with wild-type animals. These results
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indicate that both Mrp2 and Bcrp1 are important determinants of methotrexate
distribution but that Mrp2 is better able than Bcrp1 to compensate for the loss of the other
transporter (107). Triple knockout Mrp2;Mrp3;Bcrp1-/- mice retained 67% of an
intravenous dose of methotrexate in their livers 1 h after administration compared with
wild-type mice that had only 7% of the dose remaining. These results highlight the
overlapping functional roles of Mrp2, Mrp3, and Bcrp1 in biliary excretion of toxic
metabolites (108).

BCRP is expressed in lactating mammary glands and has a demonstrated role in active
efflux of xenobiotics into milk. Levels of topotecan, the H2 blocker cimetidine, and the
antibiotic nitrofurantoin, as well as the dietary carcinogen 2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine (PhIP), were significantly lower in milk from Bcrp1-/- mice
than from wild-type mice (109-110). The involvement of BCRP in the secretion of toxic
compounds into breast milk is counterintuitive for a transporter that otherwise plays a
protective role, and avoidance of BCRP substrates may be a consideration for nursing
women. BCRP was demonstrated to concentrate riboflavin (vitamin B2) into breast milk,
an observation that may provide some insight into its physiological function in the
mammary gland (111).

Reduced-function polymorphisms in ABCG2 have been identified, and from the known
function and location of BCRP, they would be expected to increase the bioavailability of
BCRP substrates, owing to reduced efflux from enterocytes and reduced biliary
excretion. Exposure to sulfasalazine was significantly increased in healthy volunteers
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with one or more ABCG2 variants following oral administration of the drug (112-113).
These findings were consistent with increased oral bioavailability and reduced excretion
of sulfasalazine in Bcrp1-/- mice (114). These results raised the possibility of using
sulfasalazine as an in vivo probe of BCRP activity, an especially attractive tool given that
expression of both mRNA and protein is highly variable in human intestinal samples and
that this variation is independent of common genetic variants (112; 115). However, a
recent pharmacokinetic study of sulfasalazine in 36 healthy volunteers failed to reproduce
these results, because the presence of the ABCG2 c.421C>A (rs2231142) polymorphism
or coadministration of the BCRP inhibitor pantoprozole showed no effect on
sulfasalazine plasma exposure or maximum plasma concentrations (116). Thus, more
work is needed to validate the utility of sulfasalazine as an in vivo probe of BCRP
activity.

The total exposure to atorvastatin and rosuvastatin is higher in individuals with the
ABCG2 c.421T>C polymorphism (74; 117), consistent with reduced biliary excretion of
rosuvastatin in Bcrp1-/- mice (118) (Table 2.1). Conversely, pitavastatin pharmacokinetics
were not influenced by the ABCG2 c.421C>A polymorphism in healthy volunteers (63),
despite the involvement of Bcrp1 in biliary excretion of pitavastatin in mice (119).
Another study linked ABCG2 polymorphism to the pharmacokinetics of fluvastatin and
simvastatin lactone, but not to the pharmacokinetics of pravastatin or simvastatin acid
(120). BCRP appears to be particularly important for the distribution of rosuvastatin, as
multiple studies have now associated reduced-function ABCG2 polymorphisms with
increased lipid-lowering response to rosuvastatin therapy in patients (75-77), presumably
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a result of increased exposure to rosuvastatin, which mimics the effect of increasing the
statin dose.

The role of BCRP in cancer treatment efficacy and prognosis has been widely studied
owing to the vast number of antineoplastic drugs that are substrates for this efflux
transporter. Indeed, ABCG2 polymorphisms have been associated with increased
exposure and/or risk for toxicity for numerous anticancer drugs in clinical use. For
example, reduced function BCRP variants were associated with higher area under the
curve and maximum concentration values of the tyrosine kinase inhibitor erlotinib; higher
trough erlotinib levels were associated with skin rash (121). Expression of BCRP in
cancer cells is generally associated with poor prognosis; however, this association has not
been demonstrated for all tumor types. In particular, BCRP expression has been linked to
poor prognosis in acute myeloid leukemia in adults and children (122-123) and to poor
prognosis in esophageal squamous cell carcinoma (ESCC) (124). Whether the association
of BCRP with reduced survival is a result of increased BCRP-mediated efflux of
anticancer drugs or a marker of more complex biology is not fully understood. BCRP is
expressed in stem cells, and indeed, some discrepancy in findings may be related to the
relative composition of the subtypes of cells in the tissue samples obtained. For a more
comprehensive review of the role of BCRP in anticancer drug efficacy, toxicity, and
overall prognosis, refer to recent comprehensive reviews (125-126).
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2.3.3

Multidrug resistance-associated proteins

Of the multidrug resistance-associated protein (MRP) family of ABC transporters, MRP1
(ABCC1), MRP2 (ABCC2), and MRP4 (ABCC4) have been most widely studied in the
context of drug response and toxicity. In some cancers, their expression may be
associated with poor overall prognosis or response to therapy (85).

2.3.3.1

Multidrug resistance-associated protein 1 in efficacy and
toxicity

MRP1 is expressed in tissues throughout the body, including the lung, testis, kidney,
cardiac and skeletal muscle, and placenta. As described above, overexpression of MRP1
in cancer cells is associated with multidrug resistance (127). Like P-glycoprotein, MRP1
is capable of transporting structurally diverse compounds. Endogenous substrates of
MRP1 include oxidized glutathione, cysteinyl leukotrienes, glucuronide and sulfate
conjugates, and drug substrates including anthracyclines, vinca alkaloids, and antivirals.
Mice lacking Mrp1 demonstrate increased sensitivity to the topoisomerase II inhibitor
etoposide (128-129). Functional ABCC1 polymorphisms have been described (130), but
to date, ABCC1 variants have not been associated with striking changes in drug response.
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2.3.3.2

Multidrug resistance-associated protein 2 in efficacy and
toxicity

MRP2 is expressed on the canalicular membrane of the hepatocyte and on the apical
membrane of proximal renal tubule endothelial cells (131). MRP2 transports a wide
range of glutathione, sulfate, and glucuronide-conjugated endo- and xenobiotics. Genetic
mutations in MRP2 cause Dubin-Johnson syndrome, a disease characterized by
hyperbilirubinemia resulting from reduced transport of conjugated bilirubin into bile
(132). Polymorphisms in ABCC2 have been associated with higher plasma concentrations
of some MRP2 substrates (133). The gastrointestinal toxicity associated with the use of
some drugs, such as NSAIDs and antibiotics, may result from enterohepatic recirculation
of these compounds and their metabolites that is driven, in large part, by MRP2 in the
bile canaliculi (134).

2.3.3.3

Multidrug resistance-associated protein 4 in efficacy and
toxicity

MRP4 is located on the basolateral membrane of hepatocytes and choroid plexus
epithelium, and the apical membrane of renal proximal tubule cells and brain capillary
endothelium (135). Localization of MRP4 to the basolateral or apical membrane,
depending on the polarized cell type, is associated with the expression of the adaptor
protein NHERF1 (136). Substrates of MRP4 include numerous endogenous compounds
involved in cellular signaling, such as cyclic nucleotides, eicosanoids, urate, and
conjugated steroids, as well as folate, bile acids, and glutathione. Drug substrates of
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MRP4 include cephalosporin antibiotics, nucleotide analog reverse transcriptase
inhibitors, and cytotoxic agents such as methotrexate and 6-mercaptopurine (135).

A SNP in ABCC4 (c.G2269A, rs3765534) caused disrupted membrane localization and
reduced MRP4 activity, and it was hypothesized to increase sensitivity to thiopurineinduced myelosuppression as a result of thiopurine metabolite accumulation in
hematopoietic cells (137). Polymorphisms in ABCC4 were reported to be associated with
side effects and survival in childhood acute lymphoblastic leukemia patients treated with
methotrexate (138); however, the same genotypes did not show any influence on the
event-free survival in adult acute lymphoblastic leukemia patients receiving methotrexate
(139).

2.4

Conclusions and future perspectives

The past decade has seen remarkable progress in the field of drug transporters, not only in
terms of functional characterization and substrate specificity but also in elucidating the
important role that transporters play in the disposition and efficacy of drugs in clinical
use. Drug interactions that target uptake or efflux transporters can often result in
unexpected systemic exposure and, in some cases, organ specific toxicity. Interestingly,
the same processes that can result in higher tissue drug accumulation can also be utilized
to produce a desirable therapeutic effect, as exemplified by the statin class of lipidlowering drugs that utilize liver-specific uptake transporters to target hepatic HMG-CoA
reductase. The next decade holds even greater promise of new discoveries relating to
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drug transporters. Indeed, as we approach the personal genomics era, the field of drug
transporter pharmacogenomics will no doubt prove to be integral to the delivery of
personalized medicine. In addition, the systematic inclusion of drug transporter studies in
the drug discovery and development process will result in drugs with greater efficacy and
reduced side effects.

Finally, the efforts of dedicated drug transporter researchers over the past half century
have resulted in a paradigm shift in our understanding of how drugs are handled by the
body. What was once thought to be predictable, on the basis of simple physicochemical
properties, has given way to our current recognition of the important role that drug
transporters play in all aspects of drug absorption, tissue distribution, and elimination.
Indeed, drug transporter research has matured and proven to be remarkably significant to
human health and optimal therapeutics.
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3

INTRODUCTION TO STATIN PHARMACOLOGY
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3.1

Therapeutic Indication

Cardiovascular disease is the leading cause of death in Canada. The burden of the disease
to our society is tremendous: in addition to claiming 30% of lives, cardiovascular disease
costs an estimated 22 billion dollars annually in direct and indirect health care expenses
and lost productivity (1). Elevated low-density lipoprotein cholesterol (LDL-C) is a major
risk factor in the development of cardiovascular disease. For many individuals, LDL-C is
a modifiable risk factor that can be reduced by a combination of lifestyle modifications
and drug therapy. One class of drugs of considerable benefit is the 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins. Meta-analysis
of statin trials indicates that a reduction of 1 mmol/L in LDL-C correlates with a 20 to
25% reduction in risk for a major cardiovascular event in patients at high risk for
cardiovascular disease (2). In Canada, current guidelines for the treatment of
dyslipidemia recommend a target LDL-C of less than 2 mmol/L, or greater than 50%
reduction of pre-treatment LDL-C. For most patients, this goal is achievable by statin
monotherapy (1).

3.2

Mechanism of Action

Statins exert their pharmacological effect by inhibiting HMG-CoA reductase, an enzyme
that catalyzes the rate-limiting step of hepatic cholesterol synthesis, which is the
production of mevalonate (3). Reduced cholesterol synthesis results in the up-regulation
of the LDL-receptor at the surface of the hepatocyte and consequently, a reduction in
plasma LDL-C. A schematic of the statin inhibition pathway is presented in Figure 3.1.
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Figure 3.1 Hepatic cholesterol synthesis pathway and mechanism of statin-mediated
reduction in LDL-C.
Statins inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis.
Reduced hepatic cholesterol results in the upregulation of the LDL receptor at the
membrane of the hepatocyte. Increased hepatic uptake reduces plasma LDL-C.
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The statin pharmacophore, which competitively binds to the active site of HMG-CoA
reductase, is similar to HMG-CoA; it is the open, acid form of this ring structure that is
active. The newer synthetic statins, such as atorvastatin and rosuvastatin, are
administered in the acid form, whereas older statins like simvastatin are administered in
the closed, lactone form. Interconversion between the two forms occurs in vivo; this may
be an enzyme mediated process or occur spontaneously (4). The pharmacological
properties of selected statins are summarized in Table 3.1.

Clinically, statin response is measured by reduction in LDL-C. The plasma concentration
of lathosterol, a late intermediate in the endogenous cholesterol synthesis pathway, can be
used to indicate the rate of endogenous cholesterol synthesis, and thus, the efficacy of
statin treatment (5).

3.3

Statin Pharmacokinetics

Statins are typically administered daily by an oral dose, and are sometimes used in
combination with other lipid-modifying therapies such as ezetimibe, fibrates or niacin,
depending on the clinical need to achieve target lipid concentration. Statins are
metabolized by members of the cytochrome P450 (CYP) enzymes, and undergo mainly
biliary excretion. The oral bioavailability of statins is limited by extensive first-pass
effect, owing to metabolism in the gut and high efficiency of portal extraction by the liver
(4; 6). The pharmacokinetic properties of selected statins are summarized in Table 3.2.
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Table 3.1 Pharmacological properties of statins
IC50

LogD

statin

form

dose

[nM]

(pH 7.0)

atorvastatin

acid

10-80

0.82

1.53

4.8

1.75

4.7

3.91

mg/day
fluvastatin

acid

20-80
mg/day

lovastatin

lactone

10-80
mg/day

pravastatin

acid

10-80

(acid -0.51)
5.0

-0.47

0.30

-0.25 to

mg/day
rosuvastatin

acid

5-40
mg/day

simvastatin

lactone

5-80
mg/day

-0.50*
5.2

4.4
(acid: 1.88)

IC50, half-maximal inhibitory concentration of HMG-CoA reductase activity in primary
cultured rat hepatocytes; LogD, distribution coefficient; *pH 7.4. References: (4; 6)
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Table 3.2 Pharmacokinetic properties of statins
bioavailtmax

Cmax

t1/2

ability

statin

(h)

(ng/mL)

(h)

(%)

metabolism

substrate?

Atorvastatin

1-2

13-67

8-21

12

CYP3A4

yes

19-29

CYP2C9

yes

(acid)
fluvastatin

Lovastatin

(40 mg)
0.5-

448

0.5-

1

(40 mg)

2.3

4

3

2.5

5

CYP3A4

yes

2

18

Not by CYP

yes

(lactone)
Pravastatin

(40 mg)
1

(acid)
Rosuvastatin

transporter

45-66
(40 mg)

5

(acid)

enzymes

19

17-

(40 mg)

20

20

CYP2C9

&

yes

CYP2C19
(both minor)

Simvastatin

1-4

(lactone)

6.9

3

<5

CYP3A4

yes

(40 mg)

Cmax, maximum concentration, tmax, time of maximum concentration t1/2, elimination halflife. References: (4; 6)
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The amphipathic chemical structure of statins limits their passage through biological
membranes by simple diffusion, and thus statins rely on active transport processes to
enter cells. Consequently, the balance of expression and activity of uptake and efflux
transporters in a particular tissue will determine the selectivity of a statin for that tissue.

Given their site of action in the liver, statins require hepatic uptake in order to exert their
effect. Statin rely on uptake transporters present on the basolateral membrane of the liver,
including organic anion-transporting polypeptides (OATPs) OATP1B1 (SLCO1B1),
OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1), and the sodium-taurocholate cotransporting polypeptide (NTCP/SLC10A1). Statins are transported into bile by ATPbinding cassette (ABC) efflux transporters on the canalicular membrane of the
hepatocyte, including P-glycoprotein (MDR1/ABCB1), breast cancer resistance protein
(BCRP/ABCG2), and multidrug resistance-associated protein 2 (MRP2/ABCC2). Statin
transporters in liver are presented in Figure 3.2.

Numerous drug-drug interactions mediated by transporters and enzymes involved in
statin distribution and metabolism have been reported. In particular, fibrates are thought
to increase statin exposure by inhibiting the OATP family of transporters (7). There are
other clinical factors that may influence statin pharmacokinetics. For example, decreased
hepatic function results in reduced statin clearance, and increased risk for statin-induced
toxicity. Age and gender have been demonstrated to affect the pharmacokinetics of some,
but not all, of the statins. Finally, ethnicity can influence statin pharmacokinetics.
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Figure 3.2 Statin transporters expressed in the human hepatocyte
BCRP, breast cancer resistance protein; MDR, multidrug resistance; MRP, multidrug
resistance-associated protein; NTCP, Na+-dependent taurocholate co-transporting
polypeptide; OATP, organic anion-transporting polypeptide
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Statin clearance is lower in Asians than Caucasians (8), and as a result, statins are
approved for half the dose in Asian countries compared with North America and Europe.
The mechanism for this effect remains unclear.

The pharmacokinetics of the most commonly prescribed statins in Canada, atorvastatin,
rosuvastatin, and simvastatin, are described in more detail below.

3.3.1

Atorvastatin pharmacokinetics

Atorvastatin is metabolized by CYP3A4 and CYP3A5, into two major hydroxylated
metabolites, ortho-hydroxy atorvastatin and para-hydroxy atorvastatin. Both metabolites
are active inhibitors of HMG-CoA reductase (9). Atorvastatin is a relatively hydrophilic
statin, and is transported by OATPs and ABC transporters. The renal elimination of
atorvastatin is less than 1% (9). Early pharmacokinetic studies demonstrated that the
mean area under the curve (AUC) of atorvastatin was approximately 23% higher in
elderly patients compared with young adults; it was approximately 11% lower in women
than men (10).

3.3.2

Rosuvastatin pharmacokinetics

Rosuvastatin does not undergo extensive metabolism, and is excreted 70% unchanged
(8). It is the most hydrophilic of the statins currently in use, and thus it relies on transport
to traverse biological membranes. Rosuvastatin is also the most potent of the statins. The
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renal elimination of rosuvastatin is 10 - 30% (6; 8). There appeared to be no significant
effect of age or gender on the pharmacokinetics of rosuvastatin (11).

3.3.3

Simvastatin pharmacokinetics

Like atorvastatin, simvastatin is metabolized by CYP3A4 and CYP3A5 (12). Simvastatin
is administered in its lactone form, and is converted into its active acid form in vivo.
Simvastatin acid inhibits OATP1B1 transport in vitro, and in healthy individuals,
SLCO1B1 polymorphisms appear to influence simvastatin pharmacokinetics more than
any other statin tested (13). Exposure to simvastatin was higher in elderly individuals and
in women compared with men (14).

3.4

Potential for Adverse Side Effects

The major challenge to statin therapy is the considerable risk for adverse side effects,
most often muscle pain or weakness, presenting with or without creatine kinase elevation.
Up to 10% of individuals will experience these side effects at some point during therapy,
requiring dose adjustment, switching to another compound in the statin class, or
eliminating the possibility of statin use altogether (15). In addition there is the risk, in less
than 1% of individuals, of developing serious adverse reactions, including a lifethreatening form of muscle damage, rhabdomyolysis (16). This is a significant concern
given that over 3 million Canadians take statins to lower LDL-C.
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The mechanisms by which statins produce muscle-related side effects are unclear. Statin
transporters expressed in human skeletal muscle include OATP2B1 (SLCO2B1), MRP1
(ABCC1), MRP4 (ABCC4), and MRP5 (ABCC5) (17). Muscle-related adverse effects are
often associated with increased statin dose and higher systemic statin exposure (18);
however, there is considerable interindividual variation in the pharmacokinetic and
pharmacodynamic profile of statins, making it very challenging to predict which
individuals will suffer from these unintended effects.

3.5

Statin Pharmacogenetics

As described in Chapter Two, polymorphisms in statin transporters have been associated
with altered statin pharmacokinetics. Some of these polymorphisms have also been
associated with clinical outcomes. In particular, the SLCO1B1 polymorphism c.521T>C
has been associated with simvastatin-induced muscle toxicity (18). The reduced function
ABCG2 variant c.421C>A has been associated with increased lipid-lowering effect from
rosuvastatin therapy (19-21). Single nucleotide polymorphisms in other genes related to
cholesterol and lipoprotein homeostasis have also been associated with variability in
statin response, however, the proportion of the pharmacodynamic variation attributed to
these polymorphisms remains small (22-24).
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3.6

The Future of Statin Use

In recent years, considerable attention has been given to the pleiotropic effects of statins,
which include improved endothelial function and plaque stability, and reduced vascular
inflammation (25). The large and highly publicized trial, Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER),
published in 2008, examined the role of the inflammatory marker C-reactive protein
(CRP) and cardiovascular risk (26). The JUPITER trial provided new evidence to suggest
statins may prevent cardiovascular events in individuals with elevated CRP but normal
cholesterol levels. These results, if confirmed, will significantly increase the number of
individuals for whom statins are indicated. The growth in statin users expected in the
coming years, resulting from such expanded indications combined with an aging
population, means that understanding statin pharmacokinetics, pharmacodynamics, and
transporter involvement will continue to be an important endeavour.
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4

SPECIFIC AIMS AND HYPOTHESES
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4.1

Specific Aim 1

To identify the molecular determinants of CCK-8 transport by OATP1B
transporters.

The unique localization of the organic anion-transporting polypeptide (OATP/SLCO) 1B
subfamily of transporters to the basolateral membrane of hepatocytes makes these
transporters desirable targets for drugs requiring hepatic entry for elimination or to exert
their effect. An understanding of the structural determinants of OATP function may
prove to be useful to the drug design process, and to predict the effect of novel
polymorphisms. OATP1B1 and OATP1B3 share nearly 80% sequence identity, and
transport many of the same drugs and endogenous substrates; however, there are notable
exceptions, such as cholecystokinin-8 (CCK-8), a gastrointestinal peptide hormone that is
transported by OATP1B3 but not by OATP1B1. The molecular determinants of CCK-8
transport by OATP1B transporters are not well understood.

We hypothesized that mutation of key divergent amino acid residues in OATP1B1
to the corresponding sequence of OATP1B3 would confer CCK-8 transport to
OATP1B1. To generate this hypothesis, we created a library of OATP1B1 and
OATP1B3 chimeras and characterized the transport of CCK-8 by these chimeras to
identify three regions of OATP1B3 involved in CCK-8 transport. We utilized sitedirected mutagenesis to alter individual amino acids in OATP1B1 to the corresponding
sequence in OATP1B3, and identified the amino acids with the greatest potential to
confer CCK-8 transport. As described in Chapter Five, we showed that three distinct
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regions of OATP1B3 are involved in CCK-8 transport. Three mutations to OATP1B1
(A45G, L545S, T615I), one in each of the three regions, were required to confer CCK-8
transport activity to OATP1B1.

4.2

Specific Aim 2

To investigate the contribution of Oatp1b2 to the hepatic uptake of atorvastatin,
rosuvastatin, and simvastatin in Oatp1b2-/- (Slco1b2-/-) mice.

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or
statins, reduce low-density lipoprotein cholesterol (LDL-C) by inhibiting the rate-limiting
step of cholesterol synthesis. To exert this effect, statins require transport-facilitated entry
into the hepatocyte, the primary site of cholesterol synthesis. Oatp1b2 is the murine
ortholog of the human transporters OATP1B1 and OATP1B3; the Oatp1b2-/- mouse thus
provides an in vivo model of the effect of loss-of-function OATP1B1 (SLCO1B1) or
OATP1B3 (SLCO1B3) polymorphisms. More background on the strengths and
limitations of using solute carrier knockout mice to assess in vivo solute carrier function
can be found in Appendix C. The effect of Oatp1b2 deletion on the pharmacokinetics of
some statins has been previously described, however, the commonly prescribed statins,
atorvastatin and rosuvastatin, have not been reported.
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We hypothesized that Oatp1b2 is involved in the hepatic uptake of atorvastatin,
rosuvastatin, and simvastatin. To test this hypothesis, we characterized the liver and
plasma concentrations of atorvastatin, rosuvastatin, and simvastatin in Oatp1b2-/- mice
after a tail vein injection of each compound. As described in Chapter Six, the liver-toplasma ratios of atorvastatin and rosuvastatin but not simvastatin were significantly lower
in Oatp1b2-/- mice compared with wild-type animals. The results indicate that Oatp1b2 is
critical for the hepatic uptake of atorvastatin and rosuvastatin.

4.3

Specific Aim 3

To characterize the intraindividual variability in pharmacokinetics of atorvastatin,
rosuvastatin, and simvastatin in healthy volunteers.

Statin use is associated with risk of muscle pain or injury, an adverse effect that is
associated with increased systemic statin exposure. Statin switching can be an effective
strategy to avoid toxicity and is often used in clinical practice (1); however, the
intraindividual variability in statin pharmacokinetics has not been well described.

We hypothesized that the relative exposure to atorvastatin, rosuvastatin, and
simvastatin in the same individual would be different. That is, those individuals with
the highest areas under the curve (AUCs) for one statin would not be the same
individuals with the highest AUCs for another statin. To test this hypothesis, we
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administered each of the three drugs to eleven healthy subjects, and calculated the AUC
of each statin over ten hours. As described in Chapter Six, the AUCs of atorvastatin and
simvastatin were correlated in this group, but the AUC of rosuvastatin was not predictive
of atorvastatin or simvastatin exposure.

4.4

Specific Aim 4

To characterize the contribution of statin transporter polymorphisms to the
interindividual variability of statin pharmacokinetics in patients.

The SLCO1B1 polymorphism c.521T>C has been identified as the single best predictor
of simvastatin-induced muscle toxicity in a genome-wide association study (2); the
mechanism of this effect is thought to be related to increased systemic exposure resulting
from reduced hepatic uptake. In addition, a polymorphism in breast cancer resistance
protein (BCRP/ABCG2), c.421C>A, has been associated with improved response to statin
therapy. This is postulated to result from increased systemic exposure resulting from
reduced statin efflux from the enterocyte into the lumen and from the hepatocyte into the
bile. Despite numerous large statin trials performed to date, to our knowledge, these
studies have not measured statin concentration.

We hypothesized that genetic variation in drug metabolizing enzymes and
transporters contributes to interindividual variability in statin pharmacokinetics in

80

patients. To test this hypothesis, we measured statin concentration in patients undergoing
routine clinical care at London Health Sciences Center, and genotyped these patients for
single nucleotide polymorphisms (SNPs) in genes involved in statin pharmacokinetics.
As described in Chapter Seven, we observed up to 45-fold interindividual variability in
circulating plasma statin concentration, among patients on the same dose. Rosuvastatin
concentration was associated with ABCG2 and SLCO1B1 polymorphisms, while only
SLCO1B1 polymorphisms were associated with atorvastatin level. Atorvastatin
concentration was also associated with 4β-hydroxycholesterol concentration, a marker of
CYP3A activity.

4.5
To

Specific Aim 5

characterize

the

association

of

lathosterol

concentration

with

statin

concentration and transporter polymorphisms in patients on statin therapy.

Given the importance of the liver to the excretion of statins, higher plasma level may
reflect reduced hepatic uptake. Thus patients with reduced SLCO1B1 function may be
expected to have reduced LDL-C lowering response, despite higher statin level.
Lathosterol is a late intermediate of cholesterol synthesis that may be used as a specific
measure of the extent of HMG-CoA reductase inhibition.
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We hypothesized that lathosterol concentration would be correlated with statin
concentration and transporter polymorphisms in patients on statin therapy. To test
this hypothesis, we measured lathosterol and total cholesterol concentration in our patient
population to assess HMG-CoA reductase inhibition. As described in Chapter Seven,
lathosterol concentration was not associated with statin concentration or SLCO1B1
polymorphism. Instead, lathosterol concentration was associated with total cholesterol
and ezetimibe use.
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5.1 Introduction
The organic anion-transporting polypeptides (OATPs; gene symbol solute carrier family
SLCO) form a superfamily of transmembrane proteins involved in the transport of a
variety of amphipathic substrates across the plasma membrane in a sodium-independent
manner. To date, over 80 members of the OATP superfamily in 13 different species have
been identified by the presence of the OATP superfamily signature D-X-RW-(I,V)GAWW-X-G-(F,L)-L. The two members of the human subfamily OATP1B, OATP1B1
(previously known as OATP-C, liver-specific transporter 1 (LST-1), or OATP2; gene
symbol SLCO1B1, previously SLC21A6) and OATP1B3 (previously known as LST-2, or
OATP8; gene symbol SLCO1B3, previously SLC21A8), share 80% sequence identity (1).
Their expression is predominantly observed on the basolateral membrane of hepatocytes,
where they mediate the hepatic uptake of substrates from the portal blood (2-5). Not
surprisingly, OATP1B1 and OATP1B3 share a broad substrate specificity, and are
capable of transporting bile salts, steroid conjugates, the thyroid hormones T3 and T4,
eicosanoids, cyclic peptides, bromosulfophthalein, the natural toxins phalloidin and
microcystin-LR as well as numerous drugs, such as methotrexate, rifampin, and many of
the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statin) family of
compounds (1; 6-8).

Reports of mice with deletion of Oatp1b2 (Slco1b2), the closest murine ortholog to
OATP1B1 and OATP1B3, described altered pharmacokinetic profiles of prototypical
OATP1B1 substrates pravastatin and rifampin (9), as well as protection from
hepatotoxicity induced by phalloidin and microcystin-LR (10). The clinical relevance of
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OATP1B1 to hepatic elimination is also evidenced by the profound effect of single
nucleotide polymorphisms (SNPs) on the observed pharmacokinetic profile of drug
substrates (7). Remarkably, a previously identified SNP in SLCO1B1 has been shown to
be the single most important predictor of statin-induced muscle myopathy, a relatively
rare but potentially fatal side effect of statin therapy (11-12).

Despite their remarkable sequence similarity and overlapping substrate specificity, there
are some notable differences in the compounds transported by OATP1B1 and OATP1B3.
For example, OATP1B3 transports the gastrointestinal peptide hormone cholecystokinin8 (CCK-8), which is not a substrate of OATP1B1 (1; 13-14). Conversely, OATP1B1
transports the steroid conjugate estrone sulfate while OATP1B3 does not show
appreciable transport activity. Accordingly, the wide and overlapping but not identical
substrate specificity of OATP1B1 and OATP1B3, combined with their significant
sequence homology, suggests that there may be key sequence differences that confer
isoform-specific divergence in substrate specificity.

Previously, transmembrane (TM) helices eight and nine were identified as important for
estrone sulfate and estradiol-17β-glucuronide transport by OATP1B1 (15), and the
mutation of four residues in TM10, Leu545, Phe546, Leu550 and Ser554, resulted in complete
loss of estrone sulfate transport (16). Conserved, positively charged amino acids in other
areas of OATP1B1 also appear to be important for estrone sulfate and estradiol-17βglucuronide transport (17). With respect to OATP1B3, previous studies have indicated a
role for TM10 in mediating CCK-8 transport (18). Similar to the case of OATP1B1,
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conserved, positively charged amino acids in OATP1B3 appear to be important for
transport of sulphobromophthalein (BSP), pravastatin, and taurocholate (19-20).

Given the importance of OATP1B1 in hepatic drug uptake, the molecular basis for
substrate specificity needs to be defined to more fully understand the in vivo distribution
of its substrates, and to aid in the rational design of drugs targeting the liver as their site
of action. In the present work, we employed a strategy of random chimeragenesis to
obtain insight to specific regions involved in CCK-8 transport. Our results indicate that
amino acid residues in three distinct regions of the transporter are required to enable
CCK-8 transport by OATP1B3. Importantly, we were able to confer CCK-8 transport by
OATP1B1 through targeted mutagenesis of amino acids in the regions noted to be
important for CCK-8 transport by OATP1B3.

5.2
5.2.1

Experimental Section
Materials

[3H]-CCK-8(L-aspartyl-L-tryosyl-L-methionylgylcyl-L-tryptophyl-L-methionyl-Laspartyl-L-phenylalaninamide hydrogen sulfate ester; 93 Ci/mmol, >97% purity) was
purchased from GE Healthcare (Buckinghamshire, UK), [3H]-estrone sulfate (57.3
Ci/mmol, >97% purity) from PerkinElmer (Boston, MA), and [3H]-atorvastatin (5
Ci/mmol, >97% purity) from American Radiolabeled Chemicals (St Louis, MO).
Unlabeled estrone sulfate was from Sigma-Aldrich (St. Louis, MO), atorvastatin was
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from Toronto Research Chemicals (North York, Canada), and cholecystokinin-8 was
from Bachem Bioscience (King of Prussia, PA).

5.2.2

OATP1B chimera plasmid construct

The master plasmids for chimeragenesis were created by inserting the coding sequence of
OATP1B1 into a previously described pEF6/V5-His TOPO plasmid containing
OATP1B3 (21). Two master plasmids with the transporters in a tandem head-to-tail
arrangement were created: OATP1B1-1B3 and OATP1B3-1B1. OATP1B1 was released
from pEF6 (12) by PCR using the Phusion High Fidelity PCR kit (New England Biolabs,
Ipswich, MA), with primers that introduced restriction enzyme sites to allow insertion of
OATP1B1 into the multiple cloning regions of pEF6-OATP1B3. For OATP1B1-1B3,
OATP1B1 was released using the forward primer 5’-ggatccacta gtccagtgtg gtggaattgc
ccttgatatc tatatttcaa-3’ and the reverse primer 5’-tctagacact agtggccgtt aacgtgctgc
atatgtgcag aattgccctt ttaacaatgt-3’, with nucleotides mutated to add HpaI, NdeI and SpeI
restriction sites in bold. The resulting fragment was ligated into pEF-OATP1B3 using
SpeI and the orientation of the fragment was confirmed by restriction digest (Figure
5.1A). For OATP1B3-1B1, the forward primer 5’ – gtccagtgcg gccgcattgc catttaaatc
tatatttcaa ccatggacca – 3’ to add NotI and SwaI sites and reverse primer 5’ – gccactgt
gctggatatc tctagaattg cccttttaac aatgtgt – 3’ to add XbaI sites were used. The resulting
fragment was ligated into pEF-OATP1B3 using NotI and XbaI (Figure 5.1B). The
resulting master plasmids OATP1B1-1B3 and OATP1B3-1B1 were linearized by HpaI
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Figure 5.1 Cloning strategy for OATP1B chimeragenesis. (A) The expression plasmid
pEF-OATP1B1-1B3 was created by ligating cDNA coding for OATP1B1 into pEF6OATP1B3 at the SpeI restriction site. The unique restriction sites NdeI and HpaI allow
for linearization of the plasmid prior to transformation and homologous recombination in
E. coli. (B) The expression plasmid pEF-OATP1B3-1B1 was created by ligating
OATP1B1 into pEF6-OATP1B3 between NotI and XbaI restriction sites in the multiple
cloning region. The unique restriction sites NotI and SwaI allow for linearization of the
plasmid prior to transformation and homologous recombination in E. coli.
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Figure 5.1 Cloning strategy for OATP1B chimeragenesis

89

and NdeI, and NotI and SwaI, respectively, and inserted into TOP10 Escherichia coli
(Invitrogen, Carlsbad, CA). Restriction fragments resulting from digesting the ensuing
plasmids with SpeI and XbaI were used to select those plasmids containing a monomeric
OATP1B sequence. OATP1B1-specific restriction enzymes were used to estimate the
approximate location of the junction between OATP1B1 and OATP1B3; sequencing
determined the exact location of the junction.

5.2.3

Site-directed mutagenesis

Single, double and triple point mutations were introduced into the coding sequence of
pEF6-OATP1B1 and pEF6-OATP1B3 using the QuikChange Multi Site-directed
Mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions.
The primers used are summarized in Table 1 of Supplementary Information I. The
presence of all mutations was confirmed by sequencing.

5.2.4

Transient transfection and transport assay

HeLa cells were plated in 12-well plates at 2.5 x 105 cells/well, to be transfected the next
day. Transporters were expressed using a transient heterologous expression system as
previously described (12). Briefly, 750 ng of cDNA was added per well as measured by
PicoGreen Assay (Invitrogen) with Lipofectin (Invitrogen) in Opti-MEM (Lonza,
Walkersville, MD). Sixteen hours later, the cells were washed in prewarmed Opti-MEM
(CCK-8) or Krebs Henseleit Bicarbonate (KHB) buffer (estrone sulfate and atorvastatin;
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1.2 mM MgSO4, 0.96 mM KH2PO4, 4.83 mM KCl, 118 mM NaCl, 1.53 mM CaCl2, 23.8
mM NaHCO3, 12.5 mM HEPES, 5 mM glucose, pH 7.4), then dosed with 400 µL of
Opti-MEM or KHB buffer containing radiolabeled substrates and varying concentrations
of unlabeled compounds, and incubated at 37 °C. Chimeric transporters and OATP1B1
mutants screened for CCK-8 transport activity (2 nM) were incubated for 30 min.
Kinetics experiments measuring uptake by the triple mutants were conducted at 10 min,
within the linear uptake phase of CCK-8 by OATP1B3. Calculations assume that CCK-8
is not extensively metabolized during the initial 10 min of uptake. Estrone sulfate uptake
(100 nM) was measured after 5 min incubation, atorvastatin uptake (75 nM) was
measured after 10 min. Cells were washed three times in ice-cold PBS, and harvested in
500 µL of 1% SDS, and radioactivity was measured by scintillation counting. Specific
uptake was determined by subtracting uptake by vector-transfected control from the total
measured. Percent OATP1B3 uptake was calculated by dividing the specific uptake of a
chimeric or mutated transporter by the specific uptake of CCK-8 by wild-type OATP1B3
during the same experiment. Statistical determination of differences was by analysis of
variance, with Dunnett’s multiple comparison test, and Student’s t test as appropriate.
The kinetic parameters Km and Vmax were calculated by Michaelis-Menten nonlinear
curve fitting (GraphPad Prism, San Diego, CA).

5.2.5

Cell surface expression and immunoblots

Cell surface biotinylation was carried out as previously described (12) to determine the
extent of cell surface trafficking of heterologously expressed transporters. Briefly, Hela
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cells (~ 8 x 105 cells/well) were transfected as described for transport experiments.
Sixteen hours post-transfection, the cells were washed in ice-cold PBS-Ca2+/Mg2+ (138
mM NaCl2, 2.7mM KCl, 1.5 mM KH2PO4, 1mM MgCl2, 0.1 mM CaCl2, pH 7.3) and
treated with sulfo-N-hydroxysuccinimide-SS-biotin (Thermo Scientific, Rockford, IL).
The cells were washed with ice-cold PBS-Ca2+/Mg2+ containing 100 mM glycine and
disrupted with lysis buffer (10 nM Tris base, 150 mM NaCl, 1 mM EDTA, 0.1% SDS,
1% Triton X-100, pH 7.4) containing protease inhibitors (Complete, Roche Applied
Science, Indianapolis, IN). Following centrifugation, 140 µL of streptavidin-agarose
beads (Thermo Scientific, Rockford, IL) were added to 600 µL of cell lysate, and
incubated for one hour at room temperature. Beads were washed four times with ice-cold
lysis buffer, and biotinylated proteins were released from the beads by adding Laemmli
buffer. Biotinylated (cell surface-expressed) fractions and total cell lysates (25µL) were
subjected to Western blotting analysis for detection of OATP1B1 or OATP1B3 by
specific polyclonal antibodies as previously described (12). The intracellular,
endoplasmic reticulum-resident protein calnexin was probed as a loading control (1:2000
dilution, StressGen, Victoria, British Columbia, Canada). Densitometry analysis was
performed using ImageJ (http://imagej.nih.gov/ij/).

92

5.3

Results

5.3.1 [3H]-CCK-8 uptake by transfected cells expressing OATP1B11B3 and OATP1B3-1B1 chimeras identifies regions in TM1, TM10
and extracellular loop 6 (ECL6) involved in CCK-8 transport. A library of
OATP1B1-1B3 and OATP1B3-1B1 chimeric expression constructs was generated using
homologous recombination of linear DNA by E. coli. Sequencing of the constructs
indicated that the chimeric junctions were well distributed throughout the coding
sequence (Figure 5.2). Screening of the chimeras for transport of CCK-8 identified three
regions of interest defined by the overlap of sequences causing altered transport activity
in both sets of chimeras. A substantial decrease in CCK-8 transport by OATP1B1-1B3
chimeras with junctions at Gly26 and Phe59 combined with a modest increase by.
OATP1B3-1B1 chimeras with junctions at Ser35 and Cys101 forms a region of interest
between Ser35 and Phe59. This region is located close to the predicted extracellular
boundary of transmembrane helix 1 (TM1). A second region of interest is formed by a
change in transport activity in OATP1B1-1B3 chimeras with junctions at Phe534 and
Asp596, and OATP1B3-1B1 chimeras with junctions at Tyr481 and Lys568, creating a
region of interest between Phe534 and Lys568. A third region is formed by the overlap of a
region responsible for a significant gain in OATP1B3-1B1 transport in chimeras with
junctions at Gly608 and Gln652 with a small but detectable decrease in CCK-8 transport in
OATP1B1-1B3 chimeras with junctions at Asp596 and Ser629. This region, defined by
Gly608 and Ser629, is located in a portion of the predicted extracellular loop (ECL) 6 close
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Figure 5.2 Identification of regions involved in CCK-8 transport
OATP1B1-1B3 and OATP1B3-1B1 chimeric constructs were generated by random
chimeragenesis, and sequencing determined the exact location of the junction as
indicated. In total, 16 OATP1B1-1B3 chimeras and 18 OATP1B3-1B1 chimeras were
expressed in HeLa cells and assayed for CCK-8 transport activity. Regions of interest in
TM1 (hatched line), TM10 (solid line) and ECL6 (dotted) formed by overlap of regions
exhibiting changes in [3H]-CCK-8 transport in both sets of chimeras were identified for
further investigation by site-directed mutagenesis. Values are expressed as means ± SEM
of n = 5 from at least two independent experiments
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to TM12. Within these regions, seven nonconserved amino acids in both TM1 and ECL6
and twelve nonconserved residues in TM10 were mutated in OATP1B1 to the
corresponding residue in OATP1B3.

5.3.2 Site-directed mutagenesis of non-conserved residues indicates
amino acids at positions 45 in TM1, 545 in TM10 and 615 in ECL 6
near TM12 contribute to CCK-8 transport. OATP1B1 mutants of
nonconserved residues in OATP1B3 located in the region of TM1 defined by the
chimeras were created by site-directed mutagenesis and screened for CCK-8 transport
(Figure 5.3). Of the seven mutants created, L36F, F38Y, T42A, A45G, S50I, I53T and
H54Q, the OATP1B1 mutant A45G showed the greatest transport activity, at 0.8% of
wild-type OATP1B3 CCK-8 transport, compared with 0.3% activity normally observed
for wild-type OATP1B1 (Figure 5.3B; p < 0.01). The corresponding mutation of
OATP1B3 to the OATP1B1 residue, OATP1B3 G45A, exhibited approximately a 35%
decrease in CCK-8 transport compared to wild-type OATP1B3 (Figure 5.3E; p < 0.001).

In the region of TM10 defined by the chimeric transporters, a total of 12 OATP1B1
mutants were created: Y535F, F536I, F537Y, L543I, L545S, F546L, L550T, S554T,
H555F, V556I, M557L, and I559T (Figure 5.3D). Of the mutations in this region,
OATP1B1 L545S exhibited the highest level of CCK-8 transport, at 0.8% of wild-type
OATP1B3 (p < 0.01). Approximately 16% of wild-type CCK-8 transport was observed
by the corresponding mutation OATP1B3 S545L (Figure 5.3E; p < 0.001).
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Figure 5.3 Uptake of [3H]-CCK-8 by cells expressing OATP1B1 and OATP1B3 mutants.
(A) Schematic of OATP1B1, including positions of residues mutated in this study.
OATP1B1 topology is as predicted by TMPred (22). Uptake of [3H]-CCK-8 by cells
transfected with OATP1B1 mutants in TM1 (B), ECL6 (C), TM10 (D) and OATP1B3
mutants (E) is expressed as % of wild-type OATP1B3 uptake ± SEM, n=4 from two
independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 relative to wild-type
OATP1B1 (B-D) and OATP1B3 (E). Amino acid sequence alignment of OATP1B1 and
OATP1B3 in regions of TM1, ECL6 and TM10 formed by overlapping areas of interest
as identified by [3H]-CCK-8 uptake by the chimeras.
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Finally, of seven OATP1B1 mutants in ECL6, T609A, R610Q, S612A, T615I, T619V,
S620F, and S622G, the OATP1B1 mutant T615I exhibited the greatest increase in CCK8 transport over wild-type OATP1B1 transport, to 1.5% of OATP1B3 transport activity
(p < 0.001). The corresponding mutation, OATP1B3 I615T, showed a close to 55%
decrease in transport activity (Figure 5.3E; p < 0.001).

To investigate the potential for interactions between two or more regions identified by the
chimeric transporters to be involved in CCK-8 transport, the double mutants OATP1B1
A45G/L545S, OATP1B1 L545S/T615I, and OATP1B1 A45G/T615I were constructed.
The double mutants exhibited 3.9, 2.2, and 2.9 % of OATP1B3 CCK-8 uptake,
respectively (Figure 5.4A). Similarly, the double mutants OATP1B3 G45A/S545L,
OATP1B3 S545L/I615T, and OATP1B3 G45A/I615T exhibited a marked, but not total,
loss of CCK-8 transport activity (Figure 5.4C).

In contrast, when a mutation from each of the three regions identified by the chimeric
transporters was combined in the triple mutant OATP1B1 A45G/L545S/T615I, a
profound gain of CCK-8 transport activity was observed, corresponding to 16% of wildtype OATP1B3 CCK-8 uptake (Figure 5.4B; p < 0.001). The corresponding triple mutant
OATP1B3 G45A/S545L/I615T exhibited almost complete abrogation of CCK-8 transport
(Figure 5.4D; p < 0.001).
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Figure 5.4 Uptake of [3H]-CCK-8 by cells expressing OATP1B1 double and triple
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Cell surface biotinylation studies were conducted to examine whether the observed
changes in transport activity were related to the cell surface expression of the transporter.
Western blot analysis indicates that there is no significant difference in cell surface
expression in those OATP1B1 mutants with altered CCK-8 transport activity (Figure
5.5A, C), suggesting that the increase in CCK-8 transport activity observed is due to
altered substrate recognition or transport capacity and does not appear to be a result of
changed levels of cell surface expressed transporter. On the other hand, reduced cell
surface expression of OATP1B3 G45A/S545L/I615T may partially account for the loss
of CCK-8 transport, though it is important to note that the mutant cell surface expression
is approximately 40% of wild-type, suggesting that the protein is not capable of CCK-8
transport (Figure 5.5D).
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Figure 5.5 Immunoblot of biotinylated fractions of OATP1B1 and OATP1B3 mutants.
Total protein lysates (biotinylated and nonbiotinylated fractions) from Hela cells
transfected with OATP1B1 (A) or OATP1B3 (B) mutants were subjected to SDS-PAGE,
transferred to nitrocellulose and blotted with anti-OATP1B1 or anti-OATP1B3 antibody,
respectively. Cell surface lysates (biotinylated fractions) from Hela cells transfected with
OATP1B1 (C) or OATP1B3 (D) were similarly probed.
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Figure 5.5 Immunoblot of biotinylated fractions of OATP1B1 and OATP1B3
mutants
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5.3.3 Characterization of CCK-8 transport kinetics of OATP1B1 triple
mutant and wild-type OATP1B3. The kinetics of CCK-8 uptake by the
OATP1B1 triple mutant A45G/L545S/T615I compared to wild-type OATP1B3 were
examined by measuring [3H]-CCK-8 uptake after 10 minutes in the presence of unlabeled
CCK-8 varying in concentration from 2 nM to 100 µM. Results indicate a higher Km
(15.4 ± 4.2 µM vs. 6.5 ± 2.0 µM) and a lower Vmax (0.020 ± 0.0018 nmol/mg protein/min
vs. 0.064 ± 0.0049 nmol/mg protein/min) for the OATP1B1 triple mutant compared to
wild-type OATP1B3 uptake (Figure 5.6). Vmax and Km for the OATP1B1-mediated
uptake of CCK-8 were undeterminable. Intrinsic clearance values (Vmax/Km) were lower
in the OATP1B1 triple mutant (1.2 µl/mg protein/min) compared to wild-type OATP1B3
(9.8 µl/mg protein/min), due to the lower Vmax and higher Km of the OATP1B1 triple
mutant.

5.3.4 Transport of other OATP1B substrates by OATP1B1 and
OATP1B3 triple mutants. The OATP1B1-specific substrate estrone sulfate was not
transported by wild-type OATP1B3 or the OATP1B3 triple mutant G45A/S545L/I615T
(Figure 5.7A). Transport of estrone sulfate by the OATP1B1 triple mutant
A45G/L545S/T615I was reduced to approximately 50% of uptake by wild-type
OATP1B1. Transport of the shared OATP1B substrate atorvastatin was modestly
increased by OATP1B1 A45G/L545S/T615I and modestly reduced by OATP1B3
G45A/S545L/I615T, compared to the cases of their respective wild-type transporters
(Figure 5.7B).
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Figure 5.6 Concentration-dependent uptake of CCK-8 by Hela cells transfected with
wild-type OATP1B3 and OATP1B1 A45G/L545S/T615I
Values are expressed as means ± SEM, n = 4 from two independent experiments . Kinetic
parameters were obtained by non-linear curve fitting.
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Figure 5.7 Transport of other OATP1B substrates. (A) Uptake of estrone sulfate by
OATP1B1,

OATP1B1

G45A/S545L/I615T

(B)

A45G/L545S/T615I,
Uptake

of

OATP1B3

atorvastatin

by

and

OATP1B1,

OATP1B3
OATP1B1

A45G/L545S/T615I, OATP1B3 and OATP1B3 G45A/S545L/I615T. Values are
expressed as means ± SEM, n=4 from two independent experiments. * p < 0.05 compared
to wild-type OATP1B1.
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5.4

Discussion

The molecular basis for the substrate specificity and transport activity of the OATP
superfamily is not well understood, despite the fact that OATP transporters are
increasingly recognized as important determinants of interindividual variation in response
to many drugs in clinical use (7). Transport by the OATPs appears to be mediated by a
Na+-independent and electroneutral process, but the precise details of the transport
mechanism, including the identity of the counterion, remain to be elucidated. Recently, it
has been demonstrated that the activity of many OATP transporters is stimulated by low
extracellular pH (22-23). Hydropathy analysis of OATP/Oatp sequences indicates that
members of the superfamily form 12 TMs with intracellular amino- and carboxy termini,
an arrangement that was shown experimentally for the murine transporter Oatp1a1 (24).
The OATPs have in common a large predicted ECL5 between TMs 9 and 10;
characterization of conserved cysteine residues in ECL5 of OATP2B1 indicates these
residues are involved in membrane trafficking and transport function (25). Other
conserved features include N-glycosylation sites in ECLs 2 and 5, and the superfamily
signature that designates the OATP family, found at the border between ECL3 and TM6
(26).

CCK-8 is a gastrointestinal peptide hormone released postprandially in response to
nutrients in the gut, and it is involved in delaying gastric emptying, as well as stimulating
pancreatic enzyme secretion, gall bladder contraction and intestinal motility (27).
Interestingly, CCK-8 appears to be transported by OATP1B3 but not by the closely
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related OATP1B1. The main goal of our current study was to identify key regions or
amino acid residues which could confer gain of CCK-8 transport function to OATP1B1.

We first noted that chimeras from each set sharing the same junction close to the middle
of the transporter (Val339), OATP1B3-1B1-6, and OATP1B1-1B3-9, demonstrated a
modest gain or significant loss of wild-type OATP1B3 CCK-8 transport, respectively,
compared to adjacent chimeras (Figure 5.2). OATP1B1-1B3-9 demonstrated higher
CCK-8 transport activity than OATP1B3-1B1-6 (Figure 5.2), consistent with other
reports that the C-terminal portion of OATP1B3 is more important for CCK-8 transport
than the N-terminal portion (18). Systematic comparison of the individual chimeric
transporter function suggested that amino acids in TM1, TM10, and ECL6 may be
important for CCK-8 transport. Given the two negatively charged aspartic acid residues
in CCK-8, it might be expected that there exists some critical interaction with positively
charged residues in the transporter, especially given the importance of positively charged
residues to OATP1B3 transport of other substrates (19-20). However, none of the
OATP1B1 mutations made were to a positively charged residue in OATP1B3. Three
nonconserved positively charged residues in OATP1B1 were substituted for an
uncharged residue at the corresponding position in OATP1B3, however, none of the three
variants, H54Q, H555F or R610Q, showed any significant increase in CCK-8 transport
(Figure 5.3B, C and D). In total, five aromatic residues, Phe38, Tyr535, Phe536, Phe537, and
Phe546 in OATP1B1 fell within the regions identified and were mutated to the
corresponding residue in OATP1B3. At three of these positions, the mutation was a
semiconserved mutation to a different aromatic residue (F38Y, Y535F, and F537Y). In
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three other positions, nonaromatic residues in OATP1B1 were converted to aromatic side
chains: L36F, H555F, and S620F. The absence of any significant gain of function in any
of these OATP1B1 mutations suggests that these residues may not be involved in the
CCK-8 transport cycle.

The mutation of an alanine at position 45 to glycine in TM1 of OATP1B1 resulted in an
increase in CCK-8 transport. It is possible that this may be attributed to the loss of bulk of
the methyl group difference between these two side chains, a consideration particularly
given that CCK-8 is a relatively large substrate. Mutation of OATP1B1 from a leucine to
a serine at position 545 adds a hydroxyl group, in addition to reducing the bulk associated
with the side chain, while the mutation of threonine at position 615 to isoleucine results
in a loss of a hydroxyl group. This suggests a possible role for the interaction of a
hydroxyl group with CCK-8 in a way that either promotes or prevents CCK-8 transport.
It is also possible that the mutations noted alter protein conformation in a way that affects
substrate specificity without directly interacting with CCK-8.

A previous report that utilized a TM domain swapping strategy indicated the importance
of TM10 in CCK-8 transport by OATP1B3 (18). It should be noted that the study by Gui
and Hagenbuch focused on the substitution of individual transmembrane spanning
domains in OATP1B3 with the corresponding TMs of OATP1B1. Accordingly, their
study was designed to detect a loss of CCK-8 transport due to the presence of an
OATP1B1-specific TM region. In the current study, we pursued a chimeragenesis
approach to generate a library of both OATP1B1-1B3 and OATP1B3-1B1 monomer
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sized chimeras to identify chimeric junctions that revealed a gain and corresponding loss
of function, without an a priori bias regarding the overall importance of TM regions
versus intracellular or extracellular loops in the transporter. Although our data confirms
TM10 is a key region for CCK-8 interaction, mutation of a single residue in TM10 is not
sufficient to impart a true gain of OATP1B1-mediated CCK-8 transport (Figure 5.3D).
Indeed, our current data reveals that the synergistic interaction with two additional
domains is essential. Although it should be noted that the overall activity of the
OATP1B1 45/545/615 triple mutant was lower than that of the wild-type OATP1B3, it is
remarkable that three targeted amino acid substitutions changed OATP1B1 from
complete inability to transport CCK-8 to attaining near 15% of OATP1B3 activity
(Figure 5.4B). Conversely, substitution of amino acids at those positions in OATP1B3 to
the corresponding residue in OATP1B1 resulted in the near complete loss of OATP1B3mediated CCK-8 uptake (Figure 5.4D), despite the fact that this mutant is expressed on
the cell surface, albeit at lower levels than those for wild-type OATP1B3 (Figure 5.5D).

The three key amino acid residues noted for CCK-8 gain of substrate specificity do not
appear to confer the opposite effect, that is, OATP1B3 gain of function for an OATP1B1specific substrate such as estrone sulfate (Figure 5.7A). Similarly, there was not a readily
discernible effect of the three amino acid residues on the transport of the shared
(OATP1B1 and OATP1B3) substrate and commonly prescribed statin, atorvastatin
(Figure 5.7B,C). Therefore, it seems the amino acids we have identified in this study,
though key residues with respect to CCK-8 transport, are not essential to conferring
OATP1B1-specific or OATP1B1 and 1B3 shared substrate specificity. This is consistent
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with a recent report that TM8 and TM9 of OATP1B1 are involved in the transport of its
steroid conjugate substrates estrone sulfate and estradiol glucuronide (15).

As is the case for other transporters, little structural data for the OATPs exists as a result
of challenges associated with the purification and crystallization of large membranebound structures. A homology model for OATP1B3 based on the crystal structures of the
glycerol-3-phosphate transporter and lactose permease from E. coli has been reported
(28-30). More recently, the structure of the multidrug transporter EmrD from E. coli has
been used to model OATP1B3 (18; 31). There appears to be significant structural
conservation in the major facilitator superfamily (MFS) of transporters (32), so these
crystal structures from bacteria may serve as models to interpret data arising from
functional characterization of the distantly related OATPs. In each of the three MFS
structures mentioned, it appears that both TM1 and TM10 partially form the pore of the
transporter, consistent with the biochemical data presented here to suggest that these
regions are involved in CCK-8 transport (Figure 5.8).

This study is important to the drug development process for a number of reasons. The
exclusive expression of OATP1B1 on the basolateral membrane of hepatocytes makes it
an attractive target for drugs requiring entry into the liver to exert their effect. Species
differences in OATP expression in the liver and other organs adds complexity to studying
human OATPs and mean that in vitro and in silico approaches may prove useful in
predicting the in vivo activity of human OATPs. In addition to species differences in
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OATP1B1
TM10
L545S

EmrD

Figure 5.8 Regions involved in CCK-8 transport by OATP1B1 and OATP1B3,
mapped to the crystal structure of the multidrug resistance protein EmrD from E.
coli
Similar results were obtained for other bacterial protein structures of the major facilitator
superfamily, the glycerol-3-phosphate transporter and lactose permease from E. coli (3031). Coordinates for the crystal structures were obtained from the Protein Data Bank
(www.pdb.org; PDB IDs 2GFP, 1PW4, and 1PV6 respectively). Sequences were aligned
using ClustalW with default settings and manually optimized with respect to secondary
structure as predicted by TMPred (33). Figure images were created in Pymol
(www.pymol.org).
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substrate specificity, there are zonal differences in OATP expression within a given
tissue. In particular, OATP1B1 is expressed in hepatocytes throughout the liver, while
OATP1B3 is expressed primarily in the perivenous hepatocytes, indicating there are
important differences in transporter regulation (34). Thus, targeting one OATP over
another has the potential to result in even greater tissue specificity.

Finally, given the importance of OATPs to the cellular uptake of many drugs, it will be
useful to have the ability to predict the functional effect of novel polymorphisms in
OATPs that will be discovered as whole genome sequencing expands into clinical
applications. At the time of this writing, there was only one reported case of a naturally
occurring polymorphism in any of the same positions as the 26 mutations in OATP1B1
presented here, Leu543Trp (rs72661137). It remains difficult to predict the precise effect
of a polymorphism in OATP1B1; however, there was a modest increase in CCK-8
transport by the Leu543Ile mutant in our study (Figure 5.3D). Given this, combined with
its proximity to the Leu545 residue identified here to be important for CCK-8 transport,
we believe it is not unreasonable to expect that Leu543 polymorphisms may alter
OATP1B1 function, and further studies of this polymorphism may be warranted.

In conclusion, hepatic uptake transporters are increasingly recognized as important
determinants of drug disposition and response. Accordingly, substrate recognition by
OATP1B1 and OATP1B3 may be an important consideration for predicting potential
transporter mediated drug interactions and rational drug design. Indeed, the substrate
specificity of OATP1B1 and OATP1B3 may also provide valuable information for
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enhancing the liver-to-plasma ratio in the design of compounds targeted to the liver. This
report is the first to identify three amino acids, 45 (TM1), 545 (TM10), and 615 (ECL6),
in distinct regions of the transporter interact to confer gain of function of transport of
CCK-8 by OATP1B1. This data contributes new insight to our understanding of substrate
specificity in these important hepatic transporters.
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4

DISPOSITION OF ATORVASTATIN, ROSUVASTATIN,
AND SIMVASTATIN IN OATP1B2-/- MICE AND
INTRAINDIVIDUAL VARIABILITY IN HUMAN
SUBJECTS 4

Reproduced with permission from: DeGorter MK, Urquhart BL, Gradhand U, Tirona
RG, Kim RB. 2011. Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in
Oatp1b2-/- Mice and Intraindividual Variability in Human Subjects. J Clin Pharmacol, in
press
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6.1

Introduction

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or
statins, are widely prescribed to reduce cardiovascular disease risk. There is considerable
interindividual variation in statin pharmacokinetics and response arising from variability
in both drug transport and metabolism (1). Patients are often switched between statins to
achieve greater efficacy or reduce side effects. However, predicting a patient's response
to other statins on the market, whether to lower cholesterol or to avoid adverse events,
remains a difficult clinical problem.

Statins exert their effect through targeted accumulation in liver, which is mediated by
hepatic uptake transporters of the organic anion-transporting polypeptide (OATP; gene
symbol SLCO) family as well as sodium-dependent taurocholate cotransporting
polypeptide (NTCP) and by efflux transporters of the ATP-binding cassette (ABC)
family, located on the basolateral and canalicular membranes of the liver, respectively
(2). In addition, atorvastatin and simvastatin share a common pathway of metabolism by
CYP3A (3-4), whereas rosuvastatin is not subject to significant metabolism (5-6). Hence,
it is likely there are both similarities and differences in the relative interplay between
specific metabolism and transport pathways and their contribution to overall drug
exposure among the various statins.

Slco1b2-/- mice have proven to be a useful in vivo model for predicting the role of two
important liver-expressed OATPs in humans, OATP1B1 and OATP1B3. Previously, we
showed that hepatic uptake and clearance of the prototypical OATP1B substrate,
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pravastatin, were significantly reduced in Oatp1b2-/- mice compared with wild-type (7).
In another study, differences between wild-type and knockout were observed for
lovastatin, but not simvastatin acid or cerivastatin, indicating that the transporter is
critical for some but not all members of the statin class (8). However, the extent of
hepatic uptake for the most widely prescribed statins, atorvastatin and rosuvastatin, in this
animal model has not been described.

Our aim was to better understand the in vivo relevance of OATP1B transporters to the
commonly prescribed statins, atorvastatin, rosuvastatin, and simvastatin, by measuring
their disposition in Slco1b2-/- mice. In addition, we addressed the role of metabolism vs
transport and intraindividual variability by comparing atorvastatin, rosuvastatin, and
simvastatin pharmacokinetics in healthy subjects given all three statins.

6.2
6.2.1

Methods
Mouse pharmacokinetic study design

Slco1b2-/- mice were created as previously described (7). Male Slco1b2-/- and wild-type
mice (8-16 weeks old; 4-6 per group) were dosed 1 mg/kg atorvastatin, rosuvastatin or
simvastatin (1% DMSO in water) by tail vein injection. After 30 minutes, animals were
euthanized by isoflurane; blood was collected into EDTA-containing tubes by cardiac
puncture and livers were excised, blotted, and weighed. Plasma was obtained by
centrifugation of blood (14,000 rpm for 20 minutes at 4 °C) and all tissues were stored at
-80 °C until analyzed by LC-MS/MS as described below. The study protocol was
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approved by the Animal Use Subcommittee of the University of Western Ontario,
London, Canada.

6.2.2

Human pharmacokinetic study design

Four females and seven males, with a mean ± SD age of 33 ± 13 years and body mass
index 23.7 ± 5.0, participated in the study. All participants provided written informed
consent. The study was approved by the Research Ethics Board of the University of
Western Ontario, London, Canada.

In an open, randomized, crossover design, participants were administered single oral
doses of 20 mg of atorvastatin, 10 mg of rosuvastatin, or 20 mg of simvastatin, with a
washout period of at least one week. One male subject did not complete the atorvastatin
arm of the study. Participants were not taking any prescription medications, with the
exception of oral contraceptives. Pregnancy tests were administered on each study day
for all female participants. Subjects were not permitted to take over-the-counter
medications or supplements for one week prior to and during the study period.

Statins were administered following an overnight fast of at least nine hours. A
standardized meal was served four hours after the dose, and a standardized afternoon
snack was served seven hours after the dose. Blood was collected 0, 0.5, 1, 1.5, 2, 3, 4, 5,
6, 7, 8, and 10 hours after dose and immediately placed on ice and separated within 20
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minutes. Plasma samples were stored at -80 °C until analysis of statin concentration by
LC-MS/MS.

6.2.3

Determination of statin concentration

Concentration of atorvastatin, rosuvastatin, or simvastatin acid in plasma was determined
by a TSQ Vantage triple-quadrupole mass spectrometer (Thermo Scientific, Pittsburgh,
PA, USA) attached to a TLX2 high performance liquid chromatography system (Thermo
Scientific). All chemical standards were purchased from Toronto Research Chemicals
(North York, Canada). Internal standards were atorvastatin-d5 for atorvastatin and
simvastatin acid, and rosuvastatin-d6 for rosuvastatin.

Liver samples were homogenized 1:1 (w/v) in 0.05% formic acid and standard curves
created using blank liver homogenates. Plasma and liver samples (100 µL) were
precipitated in 300 µL acetonitrile containing internal standard, and centrifuged for 20
minutes at 14,000 rpm at 4 °C. The supernatant was diluted 1:1 in 0.05% formic acid. A
50 µL aliquot was injected onto a Hypersil GOLD C18 column (50 x 3 mm, 5 µm
particle size; Thermo Scientific), and the analytes were separated using 0.05% formic
acid and acetonitrile starting at a ratio of 70:30 with a gradient to a ratio of 10:90.
Detection was performed by a HESI II probe (Thermo Scientific) in positive mode for
atorvastatin and rosuvastatin, and negative mode for simvastatin acid, using transitions
m/z 559.2 to 440.4 for atorvastatin, 564.1 to 255.2 for atorvastatin-d5 (positive mode),
562.3 to 402.2 for atorvastatin-d5 (negative mode), 482.1 to 258.2 for rosuvastatin, 488.0
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to 264.3 for d-rosuvastatin, and 435.0 to 319.1 for simvastatin acid. The ranges of statin
quantification were 1 to 500 ng/mL in liver and 1 to 100 ng/mL in plasma. The interday
coefficients of variation (CV%) were 5.8%, 8.9% and 14.8% for atorvastatin, rosuvastatin
and simvastatin, respectively. The bias was between 2.3% and 4.9% at 2.5 ng/ml, and
between 2.4% and 3.2% at 10 ng/ml for each of the statins measured.

6.2.4

Pharmacokinetics and statistical analysis

For the mouse study, liver-to-plasma ratios were calculated by dividing liver
concentration by plasma concentration at 30 minutes, and Slco1b2-/- vs wild-type values
were compared by Mann-Whitney U test. For the human study, area under the curve from
0 to 10 hours (AUC0-10h) was calculated by the linear trapezoid rule, and AUC0-10h for the
three different statins was compared pair-wise using Spearman correlation. To calculate
area under the curve from 0 hours to infinity (AUC0-∞), the residual area was calculated
by dividing the final concentration by the terminal rate constant (Ke), and added to
AUC0-10. Statistical analyses were performed using GraphPad Prism 5 (La Jolla, CA,
USA).
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6.3
6.3.1

Results
Atorvastatin, rosuvastatin, and simvastatin liver-to-plasma
ratios in Slco1b2-/- mice

The plasma concentration of simvastatin acid was significantly higher in wild-type
compared with Slco1b2-/- mice (P = 0.03; Figure 6.1g). The liver concentration of
atorvastatin was significantly higher in wild-type compared with Slco1b2-/- mice (P =
0.002; Figure 6.1b). The liver-to-plasma concentration ratio of a given compound is a
sensitive marker of its dependence on hepatic transport processes. Liver-to-plasma
concentration ratios of atorvastatin and rosuvastatin were 2.7-fold (P = 0.002; Figure
6.1c) and 1.9-fold (P = 0.03; Figure 6.1f) higher, respectively, in wild-type compared
with Slco1b2-/- mice, 30 minutes after a single tail vein injection of 1 mg/kg. Liver-toplasma ratios of simvastatin acid were not significantly different in Slco1b2-/- mice
compared with wild-type (P = 0.49; Figure 6.1i).

6.3.2

Intraindividual variability in atorvastatin, rosuvastatin, and
simvastatin pharmacokinetics in humans

Pharmacokinetic parameters following oral administration of 20 mg of atorvastatin, 10
mg of rosuvastatin, and 20 mg of simvastatin for each participant are summarized in
Table 6.1.
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Figure 6.1 Plasma, liver, and liver-to-plasma ratios of atorvastatin (a-c), rosuvastatin (d-f)
and simvastatin (g-i) in Slco1b2-/- mice compared to wild-type controls, 30 minutes after
a 1mg/kg intravenous dose. *, p < 0.05; **, p < 0.01

and simvastatin in Slco1b2-/- mice
0

i

400

300

200

100

0
-/-

100

2

200

at
p1
b

300

50

-/-

O

f

2

500

O

at
p1
b

2

-/-

e

-/-

ild
ty
p

2

atorvastatin in liver (ng/g)

atorvastatin liver:plasma

0

at
p1
b

w

at
p1
b

e

-/-

ild
ty
p

2

500

80

O

h
e

400

rosuvastatin liver:plasma

500

ild
ty
p

-/-

O

w

at
p1
b

1000

e

w

2

e

1500

ild
ty
p

at
p1
b

O

ild
ty
p

c

w

0

**

simvastatin acid liver:plasma

O

0

-/-

20

e

10

rosuvastatin in liver (ng/g)

e

2

40

ild
ty
p

-/-

20

2000

at
p1
b

w

2

e

w

0

e

*
simvastatin acid in liver (ng/g)

at
p1
b

ild
ty
p

20

ild
ty
p

-/-

O

w

40

w

2

e

60

at
p1
b

ild
ty
p

30

b

O

O

w

g

atorvastatin in plasma (ng/ml)

d

60

rosuvastatin in plasma (ng/ml)

a

simvastatin acid in plasma (ng/ml)

126

**

60

40

20
0

*

40

30
20

10
0

15

10

5

0

Figure 6.1 Plasma, liver, and liver-to-plasma ratios of atorvastatin, rosuvastatin,

127

Table 6.1 AUC0-10h, AUC0-∞, Cmax and tmax of atorvastatin, rosuvastatin, and simvastatin
in healthy human subjects following oral doses of 20 mg, 10 mg, or 20 mg, respectively
Atorvastatin
AUC0-10

AUC0-∞

Cmax

Rosuvastatin
tmax

AUC0-10

AUC0-∞

Cmax

Simvastatin
tmax

AUC0-10

AUC0-∞

Cmax

tmax

Subject
(ng•h/ml) (ng•h/ml) (ng/ml)

(h)

(ng•h/ml) (ng•h/ml) (ng/ml)

(h)

(ng•h/ml) (ng•h/ml) (ng/ml)

(h)

1

36.2

49.6

5.4

5

27.0

28.4

4.1

3

18.9

22.3

3.7

2

2

20.5

43.3

5.7

0.5

24.6

31.9

4.3

5

7.56

9.7

1.9

1

3

50.6

82.5

23.3

0.5

54.5

73.0

8.4

5

25.4

26.8

11.5

0.5

4

25.9

40.8

9.4

0.5

6.44

8.9

1.0

5

12.8

14.9

4.2

1.5

5

44.7 118.1 11.3

1

26.0

42.0

4.1

4

16.2

21.4

3.5

1

6

39.0

55.5

6.0

0.5

61.7

76.6

9.2

2

65.6 175.3 12.8

3

7

27.3

39.7

5.9

1.5

32.9

48.7

4.8

5

6.80

10.4

1.1

3

8

37.1

47.4

6.8

1

27.0

37.0

4.6

2

18.1

31.8

3.4

2

9

NA

NA

NA

NA

22.8

29.6

3.2

5

12.1

12.7

2.8

1

10

18.1

22.5

7.6

0.5

34.2

76.0

5.7

3

7.43

9.3

1.7

0.5

11

45.3

71.6

7.8

1.5

25.2

25.2

4.3

5

15.8

19.1

3.7

2

0.75
34.5 ± 57.1 ± 8.9 ±

1.5
31.1 ± 43.4 ± 4.9 ±

5

18.8 ± 32.2 ± 4.6 ±

(0.511.1

27.2

(0.515.2

5.4
5)

22.8

2.3 (2-5) 16.5

48.0

3.9
3)

AUC0-10, area under the curve from 0 hours to 10 hours; AUC0-∞, area under the curve
from 0 hours to infinity; Cmax, peak plasma concentration; Tmax, time of peak plasma
concentration. Summary data are given as mean ± SD, except Tmax , which is given as
median and range.
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In the same subject, AUC0-10h ranks of atorvastatin and simvastatin acid were
significantly related (Spearman r = 0.68; P = 0.035; Figure 6.2e). Rosuvastatin exposure
was not predictive of atorvastatin or simvastatin acid exposure (Figure 6.2d-f). Similar
results were obtained using AUC0-∞. There was no significant association in peak plasma
concentration (Cmax) rank between any two of the three compounds in the same individual
(Table 6.1).

6.3.3

Correlation of single time point concentrations with AUC0-10h

To determine the single time point measurement that best predicts AUC0-10h, a linear
regression between concentration at each time point and AUC0-10h was performed. For
atorvastatin, rosuvastatin, and simvastatin, the concentrations most significantly
correlated with AUC0-10h were those at 3, 5, and 4 hours, respectively (Figure 6.3).
The r2 value for simvastatin AUC0-10h vs simvastatin concentration at 4 hours is 0.7516 (P
= 0.0012) if the single individual with high simvastatin concentration is excluded from
the analysis.
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Figure 6.2 Plasma concentrations of atorvastatin (a), rosuvastatin (b) or simvastatin (c) in
healthy human subjects following oral doses of 20 mg, 10 mg, or 20 mg, respectively.
AUC0-10 parameters of atorvastatin vs rosuvastatin (d), atorvastatin vs simvastatin (e) and
simvastatin vs rosuvastatin (f) in the same individual.
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Figure 6.3 Correlation between AUC0-10h and single time points from the
pharmacokinetic profile of atorvastatin (a), rosuvastatin (b) and simvastatin (c). The time
points that are most highly correlated with AUC0-10h are shown for each drug.

a

Atorvastatin Acid (ng/ml)
3 hours post-dose

132

6

4

2

r2= 0.89
p < 0.0001

0
0

20

40

60

b

Rosuvastatin Acid (ng/ml)
5 hours post-dose

Atorvastatin AUC (ng•h/ml)

10
8
6
4

r2= 0.95
p < 0.0001

2
0
0

20

40

60

80

c

Simvastatin Acid (ng/ml)
4 hours post-dose

Rosuvastatin AUC (ng•h/ml)

15

10

5

r2= 0.96
p < 0.0001
0
0

20

40

60

80

Simvastatin AUC (ng•h/ml)

Figure 6.3 Correlation between AUC0-10h and single time points from the
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6.4

Discussion

In this study, we determined the liver-to-plasma ratios of atorvastatin, rosuvastatin and
simvastatin using the recently created Slco1b2-/- mice. The active acid forms of statins
inhibit HMG-CoA reductase; thus, their facilitated entry into liver tissue is required to
exert their lipid-lowering effect. In isolation, statin concentrations in the liver and plasma
are controlled by complex processes that remain unclear; however, the impact of uptake
transport is most sensitive to detection by the tissue-to-plasma concentration ratio. From
our data in Slco1b2-/- mice, the protein encoded by this gene, Oatp1b2, appears critical to
the hepatic uptake of atorvastatin and rosuvastatin but not simvastatin acid.

Previous studies have demonstrated a role for Oatp1b2 in the disposition of pravastatin
and lovastatin but not cerivastatin or simvastatin acid (7-8). We administered simvastatin
to the mice in its lactone form, as it is prescribed to humans, in contrast to the previous
study in which simvastatin acid was both administered and measured (8). These findings
are interesting given that the genetic variant in SLCO1B1 (c.521T>C, rs4149056) appears
to have the greatest effect on the pharmacokinetics of simvastatin acid over other statins
(9).

Although the statins were administered intravenously to the mice, and not orally as
administered to humans, in this case the route of administration is not expected to
confound the liver-specific contribution of Oatp1b2 to statin transport. The magnitude of
the difference in liver concentration compared with plasma concentration, however, may
be sensitive to statin concentration in the portal circulation. Liver-to-plasma ratio of
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pravastatin administered subcutaneously was reduced at a higher dose of pravastatin (32
µg/h) compared with a lower dose (8 µg/h) in both Slco1b2-/- and wild-type mice, due to
saturation of uptake transport (7).

In mice, unlike humans, several members of the Oatp1a family are expressed on the
basolateral membrane domain of hepatocytes (10-11). Thus, Oatp1a activity in mice
lacking Oatp1b2 may underestimate the effect of loss of OATP1B function in humans. A
knockout mouse model with targeted deletion of Oatp1a1, Oatp1a4, Oatp1a5, Oatp1a6
and Oatp1b2 has recently been reported (12), and further characterization of statin
disposition in these animals may reveal the extent to which Oatp1a transporters
contribute to hepatic statin uptake in mice. However, although Oatp1b2 is liver-specific
in its expression, members of the Oatp1a family are known to be expressed in other
organs including the intestine, and thus would complicate the overall interpretation of
such data in terms of loss of intestinal absorption vs hepatic uptake.

In this study, we characterized the intraindividual variation in the pharmacokinetics of a
single oral dose of 20 mg of atorvastatin, 10 mg of rosuvastatin, and 20 mg of simvastatin
administered at least one week apart. We observed a significant correlation between
atorvastatin and simvastatin AUC0-10h but no correlation between the AUC of
rosuvastatin and atorvastatin, or the AUC of rosuvastatin and simvastatin. There was no
correlation in Cmax between any two of the three statins studied. A previous study
reported a significant correlation between the AUC of atorvastatin and simvastatin, and to
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a lesser extent, the AUC of atorvastatin and rosuvastatin and the AUC of simvastatin and
rosuvastatin (13).

Taken together, the data in humans and mice reinforce the growing appreciation for the
differences in disposition of the various statins in vivo and that the disposition profile of a
statin may not always predict that of another. In humans, atorvastatin and simvastatin
appear to share common mechanisms of elimination through CYP3A4 (3-4; 14). A minor
role for CYP2C8 in simvastatin metabolism has been described (14). Rosuvastatin, in
contrast, is not subject to metabolism by CYP3A (5). The major rosuvastatin metabolite,
N-desmethyl-rosuvastatin, is formed by CYP2C9 and CYP2C19 (6). Rosuvastatin is the
most hydrophilic of the statins used in this study, and although some CYPs are involved,
the extent of metabolism is modest as 70% of rosuvastatin is eliminated unchanged (15).

All of the statins studied here are substrates of uptake and efflux transporters. We and
others have shown that rosuvastatin is a substrate of the uptake carriers OATP1B1,
OATP1B3, OATP2B1, OATP1A2, and NTCP as well as the efflux transporters Pglycoprotein (MDR1/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and
multidrug resistance-associated protein 2 (MRP2/ABCC2) (16-17). In vitro, simvastatin
was not transported by OATP1B1 (18), although simvastatin acid inhibits OATP1B1
transport (19-20). However, genetic variations in SLCO1B1 in healthy subject studies in
vivo appear to have the greatest effect on simvastatin compared with any other statin
tested (9; 21). Both simvastatin and atorvastatin also interact with P-glycoprotein in vitro
(20; 22).
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Statin intolerance is an important and frequently observed issue in clinical practice, with
up to 10% of individuals reporting muscle pain and weakness associated with statin use.
In rare cases, a life-threatening form of muscle damage, rhabdomyolysis, may occur (23).
Switching between statins, to increase efficacy or avoid toxicity, occurs relatively
frequently in clinical practice: in a recent study of routine care of more than 4,000
diabetic patients, the reported rate of statin switching was approximately 20% (24). The
data presented here provide some explanation for why switching statins may work for
some individuals in the clinical setting. Indeed, the lack of a strong association between
exposures to different members of the statin class indicates there may be other viable
options for individuals with statin intolerance. Certainly, there are few data regarding
intraindividual variation in statin pharmacokinetics and whether those individuals with
the highest exposure to one statin have the highest exposures across all the statins. An
important finding from the current study is that there may be some predictability between
statins that undergo CYP3A metabolism as well as transport, such as atorvastatin and
simvastatin, but such a correlation is lost when considering statins such as rosuvastatin,
which is mainly subject to transport.

Finally, we identified a single time point blood sampling for the measurement of
atorvastatin, rosuvastatin, and simvastatin that best correlates with the overall AUC0-10h,
thereby streamlining the design of future studies of statin pharmacokinetics, particularly
those involving patients where simplicity and predictability are essential. In the way that
one measurement of midazolam has been successfully used to predict total exposure to
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midazolam and CYP3A activity (25), a single statin measurement will be a cost effective
and less invasive method of phenotyping for statin disposition.
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Kim RB. Clinical and pharmacogenetic predictors of circulating atorvastatin and
rosuvastatin concentration in patients. 2012.
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7.1

Introduction

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or
statins, are commonly prescribed and proven to be highly effective in reducing
cardiovascular event risk by lowering plasma concentration of low-density lipoprotein
cholesterol (LDL-C) (1). Not surprisingly, nearly 10% of adults residing in developed
countries are currently taking statins and it is predicted the number will grow as the
populations of such countries continue to age and maintain unhealthy lifestyles (2). A
significant barrier to statin therapy is muscle toxicity which is associated with elevated
systemic drug exposure. Up to 10% of individuals will experience statin-induced muscle
pain or weakness, and in rare cases, life-threatening rhabdomyolysis occurs (3-5).
Currently, we do not fully understand the drug exposure necessary for optimal statin
therapy, making it difficult to predict an individual’s dose requirement to maximize LDLC lowering, while minimizing the risk for muscle injury.

Remarkably few data are available regarding interpatient variability in plasma statin
level, especially considering the number of large multicentre clinical trials of
cardiovascular outcomes with statins performed to date. Until recently, drug metabolizing
enzymes such as cytochrome P450 enzymes (CYPs) were considered to be the major
determinants of statin disposition. However, studies from our laboratory and many others
clearly suggest that statins, particularly the pharmacologically active acid forms of
statins, are highly dependent on drug transporter proteins for their disposition and
efficacy (Figure 7.1) (6-7).
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Figure 7.1 Statin transporters in the hepatocyte and enterocyte. Transport mechanisms are
required for statin absorption in the intestine, entry into the liver, and elimination through
bile. The primary site of action for the statins is the hepatocyte, where the drugs inhibit 3hydroxy-3-methylglutaryl-coenzyme A reductase, the enzyme catalyzing the rate-limiting
step of cholesterol synthesis. Uptake transporters mediating statin absorption and hepatic
entry are members of the organic anion transporting polypeptide (OATP) family (gene
symbol SLCO), while statin efflux is mediated by members of the ATP-binding cassette
(ABC) family of transporters. Transporters present in the enterocyte include the uptake
transporter OATP2B1 (SLCO2B1) and the efflux transporters encoded by the genes
ABCG2 and ABCB1. In the hepatocyte, statin uptake is mediated by transporters
expressed on the basolateral membrane, including OATP1B1 (SLCO1B1), OATP1B3
(SLCO1B3), and OATP2B1. Statins are effluxed into the bile by ABC transporters on the
canalicular membrane, including ABCB1, ABCC2, and ABCG2.
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The relationship between drug transporter polymorphisms and plasma statin
concentration in the real world clinical situation is not presently understood. Thus, our
objective was to characterize in a patient population the interindividual variability in
statin concentration and the relative importance of uptake and efflux transporter
polymorphisms and clinical variables to plasma statin concentration. We measured 4βhydroxycholesterol concentration as a marker of CYP3A metabolic activity in vivo. In
addition, we measured lathosterol concentration to assess the efficacy of statin-mediated
inhibition of endogenous cholesterol synthesis, and its relationship to statin
concentration. Taken together, these data describe the relative contribution of transport
genetics and metabolism to the explainable interindividual variability in statin
pharmacokinetics and response.

7.2
7.2.1

Methods
Study population

We prospectively invited outpatients at London Health Sciences Center (London,
Canada) aged 18 years and older who were taking a stable dose of atorvastatin or
rosuvastatin to participate. The study was conducted between August 2009 and May
2011. A single venous 8 mL blood sample was drawn into EDTA-containing tubes, and
placed immediately on ice. Samples were centrifuged 2,000 x g for 10 minutes; plasma
was collected and stored at -80 °C until further analysis. Genomic DNA was isolated
from blood samples using the Gentra Puregene extraction kit (Qiagen, Alameda, CA,
USA). A detailed medical history was obtained, and the time the individual last took their
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oral statin dose was recorded. Ethnicity was self-reported. LDL-C response was defined
by attainment of LDL-C target values according to the 2009 Canadian Lipid Guidelines
(1) and by the clinical judgment of the treating physician. All subjects provided informed
written consent. The study protocol was approved by the Research Ethics Board of the
University of Western Ontario (London, Canada).

7.2.2

Determination of plasma statin concentration

All chemical and deuterated standards were obtained from Toronto Research Chemicals
(North York, Canada). Plasma aliquots of 100 µL were precipitated in 300 µL
acetonitrile containing internal standard d5-atorvastatin or d6-rosuvastatin, and
centrifuged at 14,000 rpm for 20 minutes at 4 °C. The supernatant was diluted 1:1 in
0.05% formic acid. Analytes were separated using mobile phases 0.05% formic acid in
water and 0.05% formic acid in acetonitrile, starting at a ratio of 70:30, with a gradient to
ratio of 10:90. Concentrations of rosuvastatin and atorvastatin were measured with by
liquid chromatography-mass spectrometry (LCMS) instrumentation and transitions as
previously described (8).

7.2.3

Determination of lathosterol and 4β-hydroxycholesterol
concentrations

Sterol concentrations were measured according to published methods for LCMS (9-10).
Lathosterol, 4β-hydroxycholesterol, and 4β-hydroxycholesterol-d7 were obtained from
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Avanti Polar Lipids (Alabaster, Alabama), and lathosterol-d4 was obtained from CDN
Isotopes (Pointe-Claire, Canada). All other chemicals for were obtained from SigmaAldrich (St. Louis, MO). Standard curves ranging from 0-50 µg/mL lathosterol were
prepared in 1% fatty acid-free bovine serum albumin in phosphate-buffered saline.
Aliquots of 50 µL of plasma or standard curve were saponified in 1 mL of 1M KOH in
ethanol for 1 hour at 37 °C. The samples were extracted twice, in 750 µL of hexanes each
time. After evaporation at 80 °C to dryness, a mixture of the following derivatization
reagents was added to each sample: 15 mg 2-methyl-6-nitrobenzoic anhydride, 4.5 mg 4dimethylaminopyridine, 12 mg picolinic acid, 225 µL pyridine, and 30 µL triethylamine.
Samples were incubated with the derivatization reagents at 80 °C for 1 hour, extracted in
1 mL of hexanes, and evaporated at 80 °C to dryness. Samples were reconstituted in 20
µL 0.9% NaCl and 80 µL water; 20 µL of sample was injected on an Eclipse Plus C18
column (1.8 µm pore size; 2.1 x 100mm; Agilent Technologies, Mississauga, Canada)
attached to an Agilent 1290 Infinity ultra high pressure liquid chromatography system
(Agilent Technologies) coupled with a TSQ Quantum triple-quadrupole mass
spectrometer (Thermo Scientific). Analytes were separated and eluted with a gradient
from 80% to 98% methanol:acetonitrile (1:1). The transition used for lathosterol was m/z
555.3 to 513.8. The transition used for 4β-hydroxycholesterol was m/z 635.4 to 146.5.
Interday variability was less than 25% for lathosterol and less than 30% for 4βhydroxycholesterol, at relevant concentrations.

148

7.2.4

Determination of total cholesterol

Total cholesterol was measured by the enzymatic colorimetric method, using the
Cholesterol E kit from Wako (Richmond, VA). Samples were measured in triplicate
using the microplate procedure, according to manufacturer’s directions.

7.2.5

Genotyping

Genotype was determined by TaqMan assay (Applied Biosystems, Foster City, CA) for
uptake transporter polymorphisms SLCO1B1 c.388A>G (rs2306283); SLCO1B1
c.521T>C (rs4149056); SLCO1B3 c.699G>A (rs7311358); SLCO2B1 c.935G>A
(rs12422149), and efflux transporter polymorphisms ABCB1 c.3435C>T (rs1045642);
ABCC2 c.1249G>A (rs2273697); and ABCG2 c.421C>A (rs2231142). For the
atorvastatin group, polymorphisms in the drug metabolizing enzymes CYP3A4
(rs35599367) and CYP3A5 (rs776746) were assessed.

7.2.6

Statistical analysis

Statistical analysis was completed using the statistical software R (11). Differences in
statin concentration with respect to each dose group were assessed by Tukey’s multiple
comparisons tests. For multiple linear regression analysis, statin concentration was logtransformed to adjust for right-skew. Only those patients with blood sampling times after
the tmax of the statin were included (1.5 hours and 4.0 hours for atorvastatin and
rosuvastatin, respectively (8)). Different genetic models–dominant, co-dominant,
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recessive, and additive models–were considered for each transporter polymorphism and
the model that best described the fit with log-transformed statin concentration or
lathosterol concentration was chosen. Each polymorphism was assessed for association
with log statin concentration with a cut-off p-value of 0.20 for further inclusion in the
multiple linear regression model. SLCO1B1 c.521T>C and c.388A>G, and ABCG2
c.421C>A, were included in the model as additive models. All models were adjusted for
age, gender, body mass index (BMI), ethnicity, statin dose, and hours from last dose. Of
these variables, age, dose, and time from last dose were statistically significant. Next, the
number of concomitant medications or presence of the specific medications ezetimibe,
niacin, and fibrate were assessed for their contribution to the model and retained if p <
0.20. 4β-hydroxycholesterol values were similarly introduced into the model. In the final
model, only those variables with p < 0.05 were retained. For each final model, analysis of
variance was performed, and the explainable variability was derived from all variables
excluding dose and time from last dose.

Maximum doses predicted to result in atorvastatin or rosuvastatin concentrations less
than the 90th percentile were calculated based on our linear regression models. The 90th
percentile was defined by the atorvastatin or rosuvastatin concentrations measured in our
population and adjusted for the time of the blood sampling. Predicted concentration was
calculated for a hypothetical Caucasian patient of our average population height and
weight, and in the case of atorvastatin, 4β-hydroxycholesterol concentration. The
difference between concentrations predicted for male and female patients were divided
equally. Age was rounded to the nearest 5-year interval.
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7.3
7.3.1

Results
Patient characteristics

The patients’ baseline characteristics are summarized in Table 7.1. In total, 299 patients
were enrolled in the study, with 134 taking atorvastatin and 165 patients on rosuvastatin
therapy. Of these patients, 3 taking rosuvastatin and 6 taking atorvastatin had
undetectable statin levels, and were excluded from further analysis. Two patients taking
rosuvastatin were excluded from lathosterol-related analysis, due to inability to measure
lathosterol or total cholesterol.

7.3.2

Rosuvastatin concentration

We observed up to 45-fold variability in plasma rosuvastatin concentration among
individuals on the same dose (Figure 7.2A). In patients taking 5, 10, 20, or 40 mg
rosuvastatin daily, mean plasma concentration of rosuvastatin was 1.6 ng/mL (SD 1.8),
3.5 ng/mL (2.9), 6.3 ng/mL (5.3), and 9.8 ng/mL (8.6), respectively. There was a
significant difference in plasma rosuvastatin concentration between those taking 5 mg vs.
20 mg (p < 0.01) and 40 mg (p < 0.0001); 10 mg vs. 20 mg (p < 0.05) and 40 mg (p <
0.001); and 20 mg vs. 40 mg (p < 0.05; Figure 7.2A).
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Table 7.1 Population characteristics
Atorvastatin

Rosuvastatin

Number of patients

134

165

Male

83 (61.9%)

115 (69.7%)

Age at enrolment (years)

58.8 (12.9)

57.0 (12.7)

Caucasian

113 (83.7%)

143 (86.7%)

Body mass index (kg/m2)

29.0 (5.2)

30.1 (6.8)

Number of concomitant medications

4.9 (3.1)

4.7 (3.1)

Statin dose (mg/kg)

0.45 (0.31)

0.22 (0.15)

5 mg

--

24 (14.5%)

10 mg

22 (16.4%)

52 (31.5%)

20 mg

30 (22.4%)

47 (28.4%)

40 mg

58 (43.2%)

38 (23.0%)

80 mg

23 (17.1%)

--

Other

1 (0.7%)

4 (2.4%)

Hours from last dose

12.9 (5.0)

11.5 (5.3)

4β-hydroxycholesterol (ng/mL)

22.0 (14.1)

18.7 (11.9)

Lathosterol (µg/mL)

3.9 (2.1)

3.4 (2.2)

ABCG2 c.421A

25/268 (9.3%)

36/330 (10.9%)

SLCO1B1 c.388G

119/268 (44.4%)

145/330 (43.9%)

SLCO1B1 c.521C

30/268 (11.2%)

61/330 (18.5%)

Minor allelic frequency

Data are number (%) or mean (S.D.)
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Figure 7.2 Atorvastatin (A) plasma concentration in patients taking 10, 20, 40, or 80 mg
daily, and rosuvastatin (B) plasma concentration in patients taking 5, 10, 20, or 40 mg
daily. Blood samples were collected within 0 to 24 hours of the last oral dose. Levels are
presented as box and whisker plots with the whiskers depicting the 5th and 95th percentile;
means are depicted by +. *p < 0.05; ** p < 0.01; *** p < 0.001
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In order to assess the association of clinical and pharmacogenetic variables to the
rosuvastatin levels observed, we performed multiple linear regression analysis. Only
those patients with blood drawn at least four hours after their last oral dose were included
in this analysis (n = 130). Multiple linear regression analysis indicated that plasma
rosuvastatin concentration was higher in individuals with the reduced function hepatic
uptake transporter allele SLCO1B1 c.521C (p < 0.0001), and the reduced function efflux
transporter polymorphism ABCG2 c.421A (p < 0.05). Age also contributed to plasma
rosuvastatin level (p < 0.01) (Table 7.2). The adjusted R2 value of the model was 0.56.
Polymorphisms in transporter genes SLCO1B1 and ABCG2 contributed to 88% of the
explainable variability.

7.3.3

Atorvastatin concentration

Similar to rosuvastatin, we observed 45-fold or higher variability between patients on the
same daily atorvastatin dose (Figure 7.2B). In patients taking 10, 20, 40, or 80 mg
atorvastatin daily, mean plasma concentration of atorvastatin was 0.9 ng/mL (SD 1.0),
2.0 ng/mL (1.7), 3.0 ng/mL (3.5), and 6.0 ng/mL (8.2), respectively. There was a
significant difference in plasma atorvastatin concentration between those taking 10 mg,
20 mg, or 40 mg vs. 80 mg (p < 0.001, p < 0.01, and p < 0.05, respectively; Figure 7.2B).

Multiple linear regression analysis indicated that plasma atorvastatin concentration was
higher in individuals with the SLCO1B1 c.521C allele (p < 0.05) but lower in those

155

Table 7.2 Rosuvastatin linear regression coefficients (n = 130)
Variable

Effect (B)

p value

1

Age (yr)

0.012

0.005

2

SLCO1B1 c.521T>C

0.413

4.48e-05

3

ABCG2 c.421C>A

0.310

0.02

Adjusted for gender, ethnicity, BMI, dose, and time from last dose. Dose and time from
last dose were also significant in this model (p < 2e-16 and p = 0.0003, respectively)

